ISSN 1948-0210 (online)

World Journal of *Stem Cells*

World J Stem Cells 2015 November 26; 7(10): 1202-1221

Published by Baishideng Publishing Group Inc

WJSC World Journal of Stem Cells

A peer-reviewed, online, open-access journal of stem cells

Editorial Board

2010-2015

The *World Journal of Stem Cells* Editorial Board consists of 719 members, representing a team of worldwide experts in infectious diseases. They are from 44 countries, including Argentina (2), Australia (10), Austria (6), Belgium (3), Brazil (10), Canada (16), China (74), Cyprus (1), Czech Republic (5), Denmark (7), Egypt (2), Finland (3), France (19), Germany (36), Greece (1), Hungary (3), India (10), Iran (9), Ireland (4), Israel (10), Italy (52), Japan (55), Jordan (1), Malaysia (1), Mexico (1), Morocco (1), Netherlands (8), Norway (3), Portugal (1), Romania (1), Russia (3), Singapore (19), Slovakia (1), South Korea (45), Spain (17), Sweden (4), Switzerland (4), Thailand (1), Tunisia (1), Turkey (5), United Arab Emirates (1), United Kingdom (29), United States (233), and Venezuela (1).

Li Deng, *Chengdu*
Jian Dong, *Shanghai*
Jun Dou, *Nanjing*
Jian-Xin Gao, *Shanghai*
Zhi-Liang Gao, *Guangzhou*
Zi-Kuan Guo, *Beijing*
Zhong-Chao Han, *Tianjin*
Ling-Ling Hou, *Beijing*
Jian-Guo Hu, *Bengbu*
Yi-Ping Hu, *Shanghai*
Dong-Sheng Huang, *Guangzhou*
Jian-Hua Huang, *Yinchuan*
Jiu-Hong Kang, *Shanghai*
Dong-Mei Lai, *Shanghai*
Anskar YH Leung, *Hong Kong*
Gang Li, *Hong Kong*
Gui-Rong Li, *Hong Kong*
Jin-Jun Li, *Shanghai*
Xiang-Yun Li, *Baoding*
Xiao-Rong Li, *Tianjin*
Zong-Jin Li, *Tianjin*
Qi-Zhou Lian, *Hong Kong*
Hong Liao, *Nanjing*
Kai-Yan Liu, *Beijing*
Lei Liu, *Chengdu*
Yi-Jia Lou, *Hangzhou*
Pauline Po Yee Lui, *Hong Kong*
Xue-Tao Pei, *Beijing*
Cai-Ping Ren, *Changsha*
Chun-Meng Shi, *Chongqing*
Guan-Bin Song, *Chongqing*
Jing-He Tan, *Tanan*
Kent Kam Sze Tsang, *Hong Kong*
Jin-Fu Wang, *Hangzhou*
Tie-Qiao Wen, *Shanghai*
Ji Wu, *Shanghai*
Ren-Hua Wu, *Shantou*
Rui-An Xu, *Xiamen*
Chuan Ye, *Guiyang*
Xi-Yong Yu, *Guangzhou*
Hao Zhang, *Beijing*
Shu-Ren Zhang, *Beijing*
Yun-Hai Zhang, *Hefei*
Lei Zhao, *Wuhan*
Xiao-Gang Zhong, *Nanning*
Bo Zhu, *Chongqing*
Zhong-Min Zou, *Chongqing*

Cyprus

Pantelis Georgiades, *Nicosia*

Czech Republic

Eva Bártová, *Brno*
Petr Dvorak, *Brno*
Vladimir Holan, *Prague*
Jaroslav Mokry, *Hradec Kralove*
Jakub Suchánek, *Hradec Kralove*

Denmark

Basem M Abdallah, *Odense*
Poul Hyttel, *Frederiksberg*
Lin Lin, *Tjele*
Morten Meyer, *Blommenslyst*
Nedime Serakinci, *Vejle*
Soren Paludan Sheikh, *Odense*
Vladimir Zachar, *Aalborg*

Egypt

Mohamed Ahmed Ghoneim, *Mansora*
Alaa Eldin Ismail, *Cairo*

Finland

Jukka Partanen, *Helsinki*
Petri Salven, *Helsinki*
Heli Teija Kristiina Skottman, *Tampere*

France

Ez-Zoubir Amri, *Nice*
Bernard Binetruy, *Marseille*
Alain Chapel, *Far*
Yong Chen, *Paris*
Dario Coleti, *Paris*
Christelle Coraux, *Reims*
Anne Claude Fernandez, *Montpellier*
Loïc Fouillard, *Cergy-Pontoise*
Norbert-Claude Gorin, *Paris*
Enzo Lalli, *Valbonne*
Gwendal Lazennec, *Montpellier*
Nathalie Lefort, *Evry*
Laurent Lescaudron, *Nantes*
David Magne, *Villeurbanne*
Muriel Perron, *Orsay*
Xavier Thomas, *Lyon*
Ali G Turhan, *Villejuif*
Didier Wion, *Grenoble*

Germany

Nasreddin Abolmaali, *Dresden*
James Adjaye, *Berlin*
Halvard Bonig, *Frankfurt*
Sven Brandau, *Essen*
Christian Buske, *Ulm*
Federico Calegari, *Dresden*
Denis Corbeil, *Dresden*
Hassan Dihazi, *Goettingen*
Juergen Dittmer, *Halle/Saale*
Thomas Dittmar, *Witten*
Frank Edenhofer, *Bonn*
José Tomás Egaña Erazo, *Munich*
Ursula Margarethe Gehling, *Langen*
Alexander Ghanem, *Bonn*
Eric Gottwald, *Eggenstein-Leopoldshafen*
Gerhard Gross, *Braunschweig*
Kaomei Guan, *Goettingen*
Christel Herold-Mende, *Heidelberg*
Jorg Kleeff, *Munich*
Gesine Kögler, *Düsseldorf*
Steffen Koschmieder, *Muenster*
Nan Ma, *Rostock*
Ulrich R Mahlknecht, *Homburg/Saar*
Ulrich Martin, *Hannover*
Glenn Mcgee, *Berlin*
Kurt Paul Pfannkuche, *Cologne*
Michael Platten, *Heidelberg*
Arjang Ruhparwar, *Heidelberg*
Heinrich Sauer, *Giessen*
Richard Schäfer, *Tübingen*
Nils Ole Schmidt, *Hamburg*
Sonja Schrepfer, *Hamburg*
Dimitry Spitkovsky, *Cologne*
Bodo-Eckehard Strauer, *Düsseldorf*
Sergey V Tokalov, *Dresden*
Wolfgang Wagner, *Aachen*

Greece

Nicholas P Anagnou, *Athens*

Hungary

Ferenc Uher, *Dioszegiut*

India

Anirban Basu, *Haryana*
Chiranjib Chakraborty, *Vellore*
Gugdutta U Gangenahalli, *New Delhi*
Minal Garg, *Lucknow*
Devendra K Gupta, *New Delhi*
Asok Mukhopadhyay, *New Delhi*
Riaz Ahmad Shah, *Kashmir*
Prathibha Harish Shetty, *Navi Mumbai*
Anjali Suhas Shiras, *Maharashtra*
Malancha Ta, *Bangalore*

Iran

Hossein Baharvand, *Tehran*
Mohamadreza B Eslaminejad, *Tehran*
Iraj Ragerdi Kashani, *Tehran*
Mansoureh Movahedin, *Tehran*
Seyed Javad Mowla, *Tehran*
Ghasem Hosseini Salekdeh, *Tehran*
Masoud Soleimani, *Tehran*
M Mehdi Yaghoobi, *Ostandari St. Kerman*
Arash Zaminy, *Tehran*

Ireland

Frank P Barry, *Galway*
Leo Quinlan, *Galway*
Philippe Taupin, *Dublin*
Ralf Michael Zwacka, *Galway*

Israel

Nadir Askenasy, *Petach Tikva*
Zeev Blumenfeld, *Haifa*
Benayahu Dafna, *Tel Aviv*
Benjamin Dekel, *Tel-Hashomer*
Dan Gazit, *Jerusalem*
Gal Goldstein, *Tel-Hashomer*
Eran Meshorer, *Jerusalem*
Rachel Sarig, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*
Shimon Slavin, *Tel Aviv*

Italy

Andrea Barbuti, *Milan*

Carlo Alberto Beltrami, *Udine*
Bruno Bonetti, *Verona*
Paola Bruni, *Florence*
Laura Calzà, *Ozzano Emilia*
Giovanni Camussi, *Turin*
Domenico Capone, *Naples*
Francesco Carinci, *Ferrara*
Carmelo Carlo-Stella, *Milan*
Clotilde Castaldo, *Naples*
Angela Chambery, *Caserta*
Massimo De Felici, *Rome*
Enzo Di Iorio, *Zelarino*
Francesco Dieli, *Palermo*
Massimo Dominici, *Modena*
Stefania Filosa, *Naples*
Guido Frosina, *Genova*
Pompilio Giulio, *Milan*
Antonio Graziano, *Naples*
Brunella Grigolo, *Bologna*
Annalisa Grimaldi, *Varese*
Angela Gritti, *Milan*
Alessandro Isidori, *Pesaro*
Caterina AM La Porta, *Milan*
Giampiero La Rocca, *Palermo*
Giampiero Leanza, *Trieste*
Enrico Lucarelli, *Bologna*
Margherita Maioli, *Sassari*
Ferdinando Mannello, *Urbino*
Tullia Maraldi, *Modena*
Gianvito Martino, *Milan*
Monica Mattioli-Belmonte, *Ancona*
Fabrizio Michetti, *Rome*
Gabriella Minchiotti, *Naples*
Roberta Morosetti, *Rome*
Gianpaolo Papaccio, *Naples*
Felicita Pedata, *Florence*
Maurizio Pesce, *Milan*
Anna Chiara Piscaglia, *Rome*
Vito Pistoia, *Genova*
Francesca Pistollato, *Ispra*
Alessandro Poggi, *Genova*
Domenico Ribatti, *Bari*
Sergio Rutella, *Rome*
Sonia Scarfi', *Genova*
Arianna Scuteri, *Monza*
Luca Steardo, *Rome*
Gianluca Vadalà, *Rome*
Maria Teresa Valenti, *Verona*
Carlo Ventura, *Bologna*
Stefania Violini, *Lodi*

Japan

Manabu Akahane, *Nara*
Yasuto Akiyama, *Shizuoka*
Tomoki Aoyama, *Kyoto*
Sachiko Ezoe, *Osaka*
Yusuke Furukawa, *Tochigi*
Masayuki Hara, *Osaka*
Eiso Hiyama, *Hiroshima*
Kanya Honoki, *Kashihara*
Yuichi Hori, *Kobe*
Susumu Ikehara, *Osaka*
Ken-ichi Isobe, *Aichi*
Masamichi Kamihira, *Fukuoka*
Yonehiro Kanemura, *Osaka*
Hiroshi Kanno, *Yokohama*
Masaru Katoh, *Tokyo*
Eihachiro Kawase, *Kyoto*
Toru Kondo, *Sapporo*
Toshihiro Kushibiki, *Osaka*
Tao-Sheng Li, *Yamaguchi*
Yasuhisa Matsui, *Sendai*
Taro Matsumoto, *Tokyo*
Yuko Miyagoe-Suzuki, *Tokyo*
Hiroyuki Miyoshi, *Ibaraki*
Hiroyuki Mizuguchi, *Osaka*
Hiroshi Mizuno, *Sendai*
Takashi Nagasawa, *Kyoto*
Kohzo Nakayama, *Nagano*
Tetsuhiro Niidome, *Kyoto*
Toshio Nikaido, *Toyama*
Shoko Nishihara, *Tokyo*
Hirofumi Noguchi, *Okayama*
Tsukasa Ohmori, *Tochigi*
Katsutoshi Ozaki, *Tochigi*
Kumiko Saeki, *Tokyo*
Masanori Sasaki, *Hokkaido*
Kazunobu Sawamoto, *Aichi*
Goshi Shiota, *Yonago*
Mikiko C Siomi, *Tokyo*
Yoshiaki Sonoda, *Osaka*
Takashi Tada, *Kyoto*
Miyako Takaki, *Nara*
Kenzaburo Tani, *Fukuoka*
Shihori Tanabe, *Tokyo*
Shuji Toda, *Saga*
Atsunori Tsuchiya, *Niigata*
Kohichiro Tsuji, *Tokyo*
Shingo Tsuji, *Osaka*
Akihiro Umezawa, *Tokyo*
Hiroshi Wakao, *Sapporo*
Yoichi Yamada, *Nagoya*
Takashi Yokota, *Kanazawa*
Yukio Yoneda, *Ishikawa*
Kotaro Yoshimura, *Tokyo*
Katsutoshi Yoshizato, *Hiroshima*
Louis Yuge, *Hiroshima*

Jordan

Khitam Salem Odeh Alrefu, *Karak*

Malaysia

Rajesh Ramasamy, *Selangor*

Mexico

Marco A Velasco-Velazquez, *Mexico City*

Morocco

Radouane Yafia, *Ouarzazate*

Netherlands

Robert Paul Coppes, *Groningen*
Dirk Gijsbert de Rooij, *Amsterdam*
Christine Mummery, *Leiden*
Vered Raz, *Leiden*
Bernardus A Johannes Roelen, *Utrecht*
Marten Piet Smidt, *Utrecht*
Frank JT Staal, *Leiden*
Ruurd Torensma, *Nijmegen*

Norway

Brynjar Foss, *Stavanger*
Zhenhe Suo, *Oslo*
Berit Bølge Tysnes, *Bergen*

Portugal

Inês M Araújo, *Coimbra*

Romania

Mihaela Chivu Economescu, *Bucharest*

Russia

Igor A Grivennikov, *Moscow*
Sergey L Kiselev, *Moscow*
Serov Oleg, *Novosibirsk*

Singapore

Yu Cai, *Singapore*
Tong Cao, *Singapore*
Jerry Chan, *Singapore*
Ken Kwok-Keung Chan, *Singapore*
Woon Khiong Chan, *Singapore*
Gavin Stewart Dawe, *Singapore*
Peter Dröge, *Singapore*
Seet Li Fong, *Singapore*
Boon Chin Heng, *Singapore*
Yunhan Hong, *Singapore*
Yuin-Han Loh, *Singapore*
Koon Gee Neoh, *Singapore*
Steve Kah Weng Oh, *Singapore*
Kian Keong Poh, *Singapore*
Seeram Ramakrishna, *Singapore*
Herbert Schwarz, *Singapore*
Winston Shim, *Singapore*
Vivek M Tanavde, *Singapore*
Shu Wang, *Singapore*

Slovakia

Lubos Danisovic, *Bratislava*

South Korea

Kwang-Hee Bae, *Daejeon*
Hyuk-Jin Cha, *Seoul*
Jong Wook Chang, *Seoul*
Kyu-Tae Chang, *Chungcheongbuk-do*
Chong-Su Cho, *Seoul*
Myung Soo Cho, *Seoul*
Ssang-Goo Cho, *Seoul*
Kang-Yell Choi, *Seoul*
Ho Jae Han, *Gwangju*
Myung-Kwan Han, *Jeonju*
Chan Yeong Heo, *Gyeonggido*

Dong-Youn Hwang, *Seongnam*
Ki-Chul Hwang, *Seoul*
Sin-Soo Jeun, *Seoul*
Youngjoon Jun, *Gyeonggi-do*
Ji-Won Jung, *Chungbuk*
Jin Sup Jung, *Gyeongsangnam-do*
Kyung-Sun Kang, *Seoul*
Gilson Khang, *Jeonju*
Byung Soo Kim, *Seoul*
Haekwon Kim, *Seoul*
Hoeon Kim, *Daejeon*
Hyo-Soo Kim, *Seoul*
Jong-Hoon Kim, *Seoul*
Mee Kum Kim, *Seoul*
Moon Suk Kim, *Suwon*
Sang Gyung Kim, *Daegu*
Song Cheol Kim, *Seoul*
Yoon Jun Kim, *Seoul*
Dong Ryul Lee, *Seoul*
Jong Eun Lee, *Seoul*
Kwang-Bok Lee, *Chonbuk*
Soo-Hong Lee, *Gyunggi-do*
Younghee Lee, *Chungbuk*
Dae-Sik Lim, *Daejeon*
Kyu Lim, *Daejeon*
Do Sik Min, *Busan*
Byung Soon Park, *Seoul*
Jong-Beom Park, *Seoul*
Gyu-Jin Rho, *Jinju*
Chun Jeih Ryu, *Seoul*
Sun U Song, *Incheon*
Jong-Hyuk Sung, *Seoul*
Jong-Ho Won, *Seoul*
Seung Kwon You, *Seoul*

Spain

Luis M Antón Aparicio, *Coruña*
Angel Ayuso-Sacido, *Valencia*
Fernando Cobo, *Granada*
Maria P De Miguel, *Madrid*
Sabrina C Desbordes, *Barcelona*
Ramon Farre, *Barcelona*
Damian Garcia-Olmo, *Madrid*
Boulaiz Houria, *Granada*
Juan M Hurle, *Santander*
Antonia Aránega Jiménez, *Granada*
Marta Muñoz Llamosas, *España*
Juan Antonio Marchal, *Granada*
Pablo Menendez, *Granada*
María Dolores Miñana, *Valencia*
Eduardo Moreno, *Madrid*
Felipe Prosper, *Navarra*
Manuel Ramírez, *Madrid*

Sweden

M Quamrul Islam, *Linkoping*
Stefan Karlsson, *Lund*
Stephen C Strom, *Stockholm*
Rachael Victoria Sugars, *Huddinge*

Switzerland

Thomas Daikeler, *Basel*
Anis Feki, *Geneva*
Sabrina Mattoli, *Basel*
Arnaud Scherberich, *Basel*

Thailand

Rangsun Parnpai, *Nakhon Ratchasima*

Tunisia

Faouzi Jenhani, *Monastir*

Turkey

Kamil C Akcali, *Ankara*
Berna Arda, *Ankara*
Alp Can, *Ankara*
Y Murat Elcin, *Ankara*
Erdal Karaoz, *Kocaeli*

United Arab Emirates

Sherif M Karam, *Al-Ain*

United Kingdom

Malcolm Ronald Alison, *London*
Charles Archer, *Cardiff*
Dominique Bonnet, *London*
Kristin Mary Braun, *London*
Wei Cui, *London*
Nicholas R Forsyth, *Stoke-on-Trent*
Rasmus Freter, *Oxford*
Hassan T Hassan, *Paisley*
David C Hay, *Edinburgh*
Wael Kafienah, *Bristol*
Francis L Martin, *Lancaster*
Stuart McDonald, *London*
Pankaj Kumar Mishra, *Wolverhampton*
Ali Mobasheri, *Leicestershire*
Mike Modo, *London*
Donald Palmer, *London*
Stefano Pluchino, *Cambridge*
Julia Margaret Polak, *London*
Stefan Alexander Przyborski, *Durham*
James Alexander Ross, *Edinburgh*
Susan Gaynor Shawcross, *Manchester*
Alastair James Sloan, *Cardiff*
Virginie Sottile, *Nottingham*
Petros V Vlastarakos, *Stevenage*
Hong Wan, *London*
Christopher M Ward, *Manchester*
Heping Xu, *Foresterhill*
Lingfang Zeng, *London*
Rike Zietlow, *Cardiff*

United States

Gregor Barr Adams, *Los Angeles*
Arshak R Alexanian, *Milwaukee*
Ali Syed Arbab, *Charlestown*
Kinji Asahina, *Los Angeles*
Atsushi Asakura, *Minneapolis*
Prashanth Asuri, *Santa Clara*
Craig S Atwood, *Madison*
Debabrata Banerjee, *New Brunswick*
David W Barnes, *Lawrenceville*
Surinder Kumar Batra, *Omaha*
Aline M Betancourt, *New Orleans*
John J Bright, *Indianapolis*
Bruce Alan Bunnell, *New Orleans*
Matthew E Burow, *New Orleans*
Anthony Wing Sang Chan, *Atlanta*
Rebecca J Chan, *Indianapolis*
Joe Y Chang, *Houston*
G Rasul Chaudhry, *Rochester*
Caifu Chen, *Foster City*
Ke Cheng, *Los Angeles*
Jonathan Donald Chesnut, *Carlsbad*
Herman S Cheung, *Coral Gables*
Kent W Christopherson II, *Chicago*
David Wade Clapp, *Indianapolis*
Claudius Conrad, *Boston*
Charles Samuel Cox Jr, *Houston*
Ronald G Crystal, *New York*
Hiranmoy Das, *Columbus*
Ivana de la Serna, *Toledo*
Marcos de Lima, *Houston*
Douglas C Dean, *Lousiville*
Bridget M Deasy, *Pittsburgh*
Weiwen Deng, *Grand Rapids*
Goberdhan Dimri, *Evanston*
David Dingli, *Rochester*
Juan Domínguez-Bendala, *Miami*
Sergey V Doronin, *Stony Brook*
Fu-Liang Du, *Vernon*
Gary L Dunbar, *Mt. Pleasant*
Todd Evans, *New York*
Toshihiko Ezashi, *Columbia*
Vincent Falanga, *Providence*
Zhongling Fen, *Oceanside*
Markus Frank, *Boston*
Mohamed A Gaballa, *Sun City*
G Ian Gallicano, *Washington*
Yair Gazitt, *San Antonio*
Sanga Gehmert, *Houston*
Yong-Jian Geng, *Houston*
Jorge A Genovese, *Salt Lake City*
Mehrnaz Gharaee-Kermani, *Ann Arbor*
Ali Gholamrezanezhad, *Baltimore*
Joseph C Glorioso, *Pittsburgh*
W Scott Goebel, *Indianapolis*
Brigitte N Gomperts, *Los Angeles*
Joel S Greenberger, *Pittsburgh*
Kristbjorn Orri Gudmundsson, *Frederick*
Preethi H Gunaratne, *Houston*
Yan-Lin Guo, *Hattiesburg*
Robert G Hawley, *Washington*
Tong-Chuan He, *Chicago*
Mary JC Hendrix, *Chicago*
Charles C Hong, *Nashville*
Yiling Hong, *Dayton*
Courtney W Houchen, *Oklahoma City*
George TJ Huang, *Boston*
Jing Huang, *Bethesda*
Johnny Huard, *Pittsburgh*
Jaclyn Y Hung, *San Antonio*
Lorraine Iacovitti, *Philadelphia*
Tony Ip, *Worcester*
D Joseph Jerry, *Springfield*
Kun-Lin Jin, *Novato*
Lixin Kan, *Chicago*
Winston Whei-Yang Kao, *Cincinnati*
Sunil Kapila, *Ann Arbor*
Partow Kebriaei, *Houston*
Mary J Kelley, *Portland*
Sophia K Khaldoyanidi, *San Diego*

Mahesh Khatri, *Wooster*
Jaspal S Khillan, *Pittsburgh*
Michael R King, *Ithaca*
Katsuhiro Kita, *Galveston*
Prasanna Krishnamurthy, *Chicago*
Marlene Anastassova Kristeva, *Van Nuys*
John S Kuo, *Madison*
Mark A LaBarge, *Berkeley*
Uma Lakshmipathy, *Carlsbad*
Hillard Michael Lazarus, *Shaker Heights*
Techung Lee, *Buffalo*
Jianxue Li, *Boston*
Joshua Li, *Charlottesville*
Shaoguang Li, *Worcester*
Shengwen Calvin Li, *Orange*
Xiao-Nan Li, *Houston*
Ching-Shwun Lin, *San Francisco*
P Charles Lin, *Nashville*
Shuo Lin, *Los Angeles*
Ning Liu, *Madison*
Suling Liu, *Ann Arbor*
Zhenguo Liu, *Columbus*
Aurelio Lorico, *Las Vegas*
Jean-Pierre Louboutin, *Philadelphia*
Bingwei Lu, *Stanford*
Qing Richard Lu, *Dallas*
Nadya L Lumelsky, *Bethesda*
Hong-Bo R Luo, *Boston*
Hinh Ly, *Atlanta*
Teng Ma, *Tallahassee*
Kenneth Maiese, *Newark*
Zubin Master, *Albany*
Debra JH Mathews, *Baltimore*
Robert L Mauck, *Philadelphia*
Lucio Miele, *Jackson*
Robert H Miller, *Cleveland*
David K Mills, *Ruston*
Murielle Mimeault, *Omaha*
Prasun J Mishra, *Bethesda*
Kalpana Mujoo, *Houston*
Masato Nakafuku, *Cincinnati*
Mary B Newman, *Chicago*
Wenze Niu, *Dallas*
Christopher Niyibizi, *Hershey*
Jon M Oatley, *Pullman*
Seh-Hoon Oh, *Gainesville*
Shu-ichi Okamoto, *La Jolla*
Frank Pajonk, *Los Angeles*
Nishit Pancholi, *Chicago*
Deric M Park, *Charlottesville*
Gregory M Pastores, *New York*
Ming Pei, *Morgantown*
Derek A Persons, *Memphis*
Donald G Phinney, *Jupiter*
John S Pixley, *Reno*
Dimitris G Placantonakis, *New York*
George E Plopper, *Troy*
Mark EP Prince, *Ann Arbor*
April Pyle, *Los Angeles*
Derek Radisky, *Jacksonville*
Murugan Ramalingam, *Gaithersburg*
Pranela Rameshwar, *Newark*
Guangwen Ren, *Piscataway*
Brent A Reynolds, *Gainesville*
Jeremy N Rich, *Cleveland*
Angie Rizzino, *Omaha*
Fred Jerrold Roisen, *Louisville*
Rouel S Roque, *Henderson*
Carl Barth Rountree Jr, *Lititz*
Clinton T Rubin, *Stony Brook*
Donald Sakaguchi, *Ames*
Paul Ronald Sanberg, *Tampa*
Gerald Phillip Schatten, *Pittsburgh*
Stewart Sell, *Albany*
Arun Sharma, *Chicago*
Jinsong Shen, *Dallas*
Ashok Kumar Shetty, *Durham*
Songtao Shi, *Los Angeles*
Yanhong Shi, *Duarte*
Vassilios I Sikavitsas, *Norman*
Igor I Slukvin, *Madison*
Shay Soker, *Winston-Salem*
Hongjun Song, *Baltimore*
Edward F Srour, *Indianapolis*
Hua Su, *Francisco*
Jun Sun, *Rochester*
Tao Sun, *New York*
Siamak Tabibzadeh, *Stony Brook*
Kenichi Tamama, *Columbus*
Masaaki Tamura, *Manhattan*
Tetsuya S Tanaka, *Notre Dame*
Dean G Tang, *Smithville*
Hugh S Taylor, *New Haven*
Jonathan L Tilly, *Boston*
Jakub Tolar, *Minneapolis*
Deryl Troyer, *Manhattan*
Scheffer Chuei-Goong Tseng, *Miami*
Cho-Lea Tso, *Los Angeles*
Andre Van Wijnen, *Worcester*
Lyuba Varticovski, *Bethesda*
Tandis Vazin, *Berkeley*
Kent E Vrana, *Hershey*
Qi Wan, *Reno*
Charles Wang, *Los Angeles*
Guo-Shun Wang, *New Orleans*
Lianchun Wang, *Athens*
Limin Wang, *Ann Arbor*
Shu-Zhen Wang, *Birmingham*
Yigang Wang, *Cincinnati*
Zack Z Wang, *Scarborough*
Zhiqiang Wang, *Duarte*
David Warburton, *Los Angeles*
Li-Na Wei, *Minneapolis*
Christof Westenfelder, *Salt Lake City*
Marc Adrian Williams, *Rochester*
J Mario Wolosin, *New York*
Raymond Ching-Bong Wong, *Irvine*
Joseph C Wu, *Stanford*
Lizi Wu, *Gainesville*
Ping Wu, *Galveston*
Sean M Wu, *Boston*
Wen-Shu Wu, *Scarborough*
Meifeng Xu, *Cincinnati*
Xiaowei Xu, *Philadelphia*
Yan Xu, *Pittsburgh*
Dean Takao Yamaguchi, *Los Angeles*
Jun Yan, *Louisville*
Feng-Chun Yang, *Indianapolis*
Jing Yang, *Orange*
Phillip Chung-Ming Yang, *Stanford*
Shang-Tian Yang, *Columbus*
Xiaoming Yang, *Seattle*
Youxin Yang, *Boston*
Kaiming Ye, *Fayetteville*
Pampee Paul Young, *Nashville*
Hui Yu, *Pittsburgh*
John S Yu, *Los Angeles*
P Hong Yu, *Miami*
Seong-Woon Yu, *East Lansing*
Xian-Min Zeng, *Novato*
Ming Zhan, *Baltimore*
Baohong Zhang, *Greenville*
Chengcheng Zhang, *Dallas*
Qunzhou Zhang, *Los Angeles*
Yan Zhang, *Houston*
Ying Zhang, *Baltimore*
Pan Zheng, *Ann Arbor*
X Long Zheng, *Philadelphia*
Xuesheng Zheng, *Charlestown*
John F Zhong, *Los Angeles*
Bin Zhou, *Boston*
Feng C Zhou, *Indianapolis*
Xianzheng Zhou, *Minneapolis*

Venezuela

Pedro M Aponte, *Estado Aragua*

WJSC

World Journal of Stem Cells

Contents

Monthly Volume 7 Number 10 November 26, 2015

World Journal of Stem Cells
Volume 7 Number 10 November 26, 2015

Contents

NAME OF JOURNAL
World Journal of Stem Cells

ISSN
ISSN 1948-0210 (online)

LAUNCH DATE
December 31, 2009

FREQUENCY
Monthly

Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

PUBLICATION DATE
November 26, 2015

World Journal of Stem Cells

Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4252/wjsc.v7.i10.1202

World J Stem Cells 2015 November 26; 7(10): 1202-1214
ISSN 1948-0210 (online)

REVIEW

Dedifferentiated fat cells: A cell source for regenerative medicine

Medet Jumabay, Kristina I Boström

Medet Jumabay, Kristina I Boström, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, United States

Kristina I Boström, the Molecular Biology Institute at UCLA, Los Angeles, CA 90095-1570, United States

Author contributions: All the authors contributed to this paper.

Supported by In part by the American Heart Association (Medet Jumabay); NIH grants P01 HL30568, R01 HL81397, and R01 HL112839 (Kristina I Boström).

Conflict-of-interest statement: The authors declare that there is no conflict of interest.

Correspondence to: Medet Jumabay, MD, PhD, Division of Cardiology, David Geffen School of Medicine at UCLA, Box 951679, Los Angeles, CA 90095-1679, United States. mjumabay@mednet.ucla.edu
Telephone: +1-310-2674951
Fax: +1-310-2068553

Received: January 22, 2015
Peer-review started: January 22, 2015
First decision: March 6, 2015
Revised: September 22, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: November 26, 2015

Abstract

The identification of an ideal cell source for tissue regeneration remains a challenge in the stem cell field. The ability of progeny cells to differentiate into other cell types is important for the processes of tissue reconstruction and tissue engineering and has clinical, biochemical or molecular implications. The adaptation of stem cells from adipose tissue for use in regenerative medicine has created a new role for adipocytes. Mature adipocytes can easily be isolated from adipose cell suspensions and allowed to dedifferentiate into lipid-free multipotent cells, referred to as dedifferentiated fat (DFAT) cells. Compared to other adult stem cells, the DFAT cells have unique advantages in their abundance, ease of isolation and homogeneity. Under proper condition *in vitro* and *in vivo*, the DFAT cells have exhibited adipogenic, osteogenic, chondrogenic, cardiomyogenc, angiogenic, myogenic, and neurogenic potentials. In this review, we first discuss the phenomena of dedifferentiation and transdifferentiation of cells, and then dedifferentiation of adipocytes in particular. Understanding the dedifferentiation process itself may contribute to our knowledge of normal growth processes, as well as mechanisms of disease. Second, we highlight new developments in DFAT cell culture and summarize the current understanding of DFAT cell properties. The unique features of DFAT cells are promising for clinical applications such as tissue regeneration.

Key words: Adipocytes; Dedifferentiated fat cells; Adult stem cells; Pluripotent stem cells; Differentiation

Core tip: Multipotent dedifferentiated fat (DFAT) cells provide evidence of plasticity in adipocytes. The newly established DFAT cells exhibit vigorous proliferation and multipotent abilities with advantages over other adult stem cells. Modified culture methods reduce the risk of contamination by cells from the stromal vascular fraction to a minimum. In *in vitro* and/or *in vivo* experiments have revealed adipogenic, osteogenic, chondrogenic,

myogenic, angiogenic and neurogenic potentials in DFAT cells. Moreover, the DFAT cells express embryonic stem cell markers and are similar to induced pluripotent stem cells in certain physiological aspects. Based on the abundance, ease of preparation, homogeneity, and multi-lineage potential, the DFAT cells are uniquely suited for regenerative medicine.

Jumabay M, Boström KI. Dedifferentiated fat cells: A cell source for regenerative medicine. *World J Stem Cells* 2015; 7(10): 1202-1214 Available from: URL: http://www.wjgnet.com/1948-0210/full/v7/i10/1202.htm DOI: http://dx.doi.org/10.4252/wjsc.v7.i10.1202

INTRODUCTION

Adipose tissue is well known to house the largest energy reserve in the body. However, adipose tissue is more than just a simple storage depot. Adipocytes secrete hormones, growth factors and cytokines, such as leptin and tumor necrosis factor-alpha, as well as proteins related to immunological and vascular functions[1-3]. Through this network of endocrine, paracrine, and autocrine signals, adipose tissue participate in energy homeostasis and is a global regulator of energy metabolism. Normal adipocyte function is also important for host defense and reproduction, and dysfunction may contribute to the development of pathological states such as insulin resistance[4,5]. Interestingly, recent research indicates that mature adipocytes can be eliminated by dedifferentiation[6-9]. With the advancement of tissue culture techniques it has been shown that mature adipocytes are able to dedifferentiate into progenitor cells, referred to as dedifferentiated fat (DFAT) cells. The DFAT cells are multipotent, and are able to redifferentiate into a variety of cell lineages[10,11]. The DFAT cells may serve as an alternative source of adult multipotent cells, with significant potential for use in tissue engineering and regenerative medicine. In this review, we focus on the recent literature addressing dedifferentiation of mature adipocytes as well as the isolation, characterization, and multipotency of DFAT cells.

DEDIFFERENTIATION, TRANSDIFFERENTIATION, AND STEM CELLS

The ultimate goal of regenerative medicine is to restore structure and function of damaged tissues and organs. To successfully support new tissue development, three regenerative processes are essential: dedifferentiation, transdifferentiation, and reprogramming of cells. These are all involved in the transition of adipocytes to DFAT cells, which may be an appropriate model for enhancing our understanding of these phenomena.

Cellular dedifferentiation is considered a regression of a cell from a highly specialized state to a simpler state that confers pluripotency, giving rise to undifferentiated progenitor cells. Transdifferentiation implies a process where one mature somatic cell transitions to another mature somatic cell. The induction of pluripotency in somatic cells is referred to as reprogramming. Stem cells are by definition able to self-renew, remain in an undifferentiated state, and differentiate along multiple cell lineages. Progenitor cells, on the other hand, exhibit less capacity for self-renewal and differentiate along one or a few lineages.

Dedifferentiation

Dedifferentiation is the basis of tissue regeneration. The first evidence of dedifferentiation during regeneration was found in plants[12,13], where it is a common process during secondary growth and wound healing. However, in mammals, the capacity to regenerate subsequent to dedifferentiation is limited. For example, myotubes in newts are able to dedifferentiate and proliferate *in vivo*[14], but this has not been shown for mouse myotubes. The *MYOD* and *MYOG* (myogenin) genes have been shown to be essential for myotube dedifferentiation. When mouse myotubes were treated with extracts from regenerating limbs of newts, *MYOD* and *MYOG* were downregulated, which allowed the myotubes to dedifferentiate and proliferate[15]. Fortunately, recent studies have demonstrated that dedifferentiation can also occur in defined situations in many cell types in human tissue[16,17].

Dedifferentiation and cell division are important intermediate processes in the process of switching phenotype, although they do not appear to be obligatory in all cases. Studies on the role of retinoblastoma protein (RB) and RB-like 2 showed that dedifferentiation of mature cardiomyocytes facilitated cardiomyocyte proliferation in cardiac hypertrophy[18]. Furthermore, inhibition of the p38 mitogen-activated protein kinase induced mammalian cardiomyocytes to dedifferentiate, which may be essential for cardiomyocyte regeneration[19,20]. However, other experimental data suggest that dedifferentiation may not be required for cardiomyocyte proliferation[21]. It has also been observed that proliferation promoted by neuregulin, an essential extracellular ligand of the epidermal growth factor receptor during cardiomyocyte development, causes cardiomyocytes to reenter the cell cycle[22,23]. Alternatively, dedifferentiation may cause cellular plasticity to emerge and allow rerouting of cells into different cell lineages. This could lead to intermediary transdifferentiation of the cell, and result in a progressive conversion into another terminally differentiated cell. Furthermore, dedifferentiation occurs during rare pathological events, which have been found in osteosarcoma, chondrosarcoma, and epithelial-myoepithelial carcinoma in humans[24-26]. A population-based study and a 20-year survey on soft tissue sarcoma also included cases of dedifferentiated liposarcoma[27].

During normal cellular development, cellular dedif-

ferentiation has been shown to relate to the regenerating cells entering the cell cycle[28]. Prolonged stress, injury, or activation of oncogenic pathways may trigger conversion of a "dedifferentiated" cell into a diseased cell, thereby opening the door for pathological changes. Hypoxia is believed to be the main factor driving the emergence of DFAT cells from adipocytes, as well as dedifferentiation of chondrocytes and smooth muscle cells[29,30]. However, more studies are needed to fully evaluate the connection between hypoxia and dedifferentiation.

Specific injuries or manipulations stimulate cellular dedifferentiation[31]. Cells lose their maturity and become susceptible to lineage modification. Dedifferentiation might occur, resulting in loss of cell function while the cells remain as undefined or resting cells as long as the insult persists. Thus, dedifferentiation would be a transition step prior to adopting a new identity, which would be distinguished by the reemergence of factors that redirect cell fate. Alternatively, dedifferentiation may be seen as an adaption to stressful stimuli, causing the cell to cease normal activity, thereby prohibiting progression toward cellular dysfunction, which in extreme cases could end in cell death. Thus, it is possible that specific changes in the intrinsic, environmental, or hormonal milieu might stimulate cells such as adipocytes to withdraw from the cell cycle, undergo dedifferentiation and acquire stem cell characteristics. Understanding the details of the dedifferentiation process would enhance our knowledge of normal regeneration.

Reprogramming

Mature cells acquire stem cell features by undergoing dedifferentiation prior to the acquisition of a new cell fate. The newly undifferentiated stem cells are primed to respond to specific cues and differentiate into a variety of cell lineages. Reprogramming can be attained through cell fusion with embryonic stem cells (ESC), somatic cell nuclear transfer, exposure to stem cell extracts, or induction of pluripotency by defined factors generating what are referred to as induced pluripotent stem cells (iPSCs). During the reprogramming, an erasure and remodeling of epigenetic marks occur including DNA methylation and modification of histone and chromatin structures[32]. A major challenge in the field of iPSCs is to convert mature cells into pluripotent cells resembling ESC for use in transplantation therapies. The reprogramming of the somatic cells is induced by the transfer of pluripotent factors, many of which are oncogenes. It has also been suggested that iPSCs might be the product of dedifferentiation of somatic cells following oncogenic insult[33,34]. To address the fear of tumorgenecity in iPSCs, a study recently showed that overexpression of core transcription factor genes or its activators support the maintenance of the cell type-specific transcriptional profile, thus inhibiting alterations in the expression of genes required for iPSC induction[35]. The stable nature of gene signatures limits dedifferentiation and promotes the cell type-specific transcriptional profiles.

Transdifferentiation

A normal, fully differentiated cell can either change its identity to a new cell type, referred to as transdifferentiation, or lose its functionality and revert to an immature state referred to as dedifferentiattion. The transition to a new phenotype may occur directly or through dedifferentiation triggered by genetic factors or environmental cues. Intermediary transdifferentiation has been shown to occur when acinar cells undergo dedifferentiation into duct-like cells with exocrine as well as endocrine potentials[36]. Another type of scenario is the conversion of phenotype without a detectable intermediate step, which is referred to as direct reprogramming. It is possible that dedifferentiated cells retrace normal development toward a different, sometimes closely related, cell lineage after reaching the progenitor state.

Different interventions, including naturally occurring events and experimental manipulations, might result in transdifferentiation of cells in unfamiliar compartments. Dedifferentiation is described as the entrance to such transdifferentiation. A recent study demonstrated that cultures of purified hepatic oval stem cells are capable of transdifferentiation into functional endocrine cells[37]. It has also been reported that increased expression of CAAT/enhancer-binding protein (C/EBP)α and C/EBPβ in differentiated islet β cells leads to reprogramming into macrophages without DNA methylation[38]. Another example is fibroblasts that have transdifferentiated into cardiomyocytes after transfer of the transcription factors GATA4, MEF2C, and TBX5[39].

The concept that terminally differentiated cells retain intrinsic plasticity increases the number of cell sources that could be used for tissue regeneration in cases of injury or disease. The generation of DFAT cells is an example of reemergence of plasticity in adipocytes, resulting in the ability to transdifferentiate into alternate cell types and to serve as a model for dedifferentiation and transdifferentiation.

DFAT cells and mesenchymal stem cells

The goal of tissue engineering is to repair and regenerate damaged organs with the help of stem cells, biomaterials, and cytokines. However, the limited availability of human stem cells that are able to differentiate along multiple lineages has hampered the progress and slowed the development of these treatments. While ESCs inherently exhibit nearly unlimited differentiation potential *in vitro* and *in vivo*, their use is constrained by scientific concerns regarding safety and efficacy, as well as by ethical, legal, and political concerns. An alternative approach is to use stem cells derived from adult tissues, which would circumvent most of these concerns.

Multipotent stem cells have been defined as a special kind of cells with a unique capacity to self-renew

indefinitely, which implies that the stem cells can be extensively expanded *ex vivo*. Human mesenchymal stem cells (MSCs) were initially derived from bone marrow, but have now been isolated from most types of tissue[40], including the brain, dermis, periosteum, skeletal muscle, synovium, trabecular bone, vasculature, and adipose tissue, which is the most abundant and accessible source of adult stem cells[41-43]. MSCs express cell surface markers like cluster of differentiation (CD)10, CD29, CD44, CD73, CD90, CD105, CD117 and STRO-1, but are negative for the hematopoietic lineage markers CD14, CD34, CD45 and HLA-DR. Identification of adipose-derived stem cells (ASCs) suggests that a pool of stem cells exists within the adult adipose tissue. The ASCs are derived from the adipose stroma vascular fraction (SVF), which includes all cells in adipose tissue except the white adipocytes. The ASCs are similar to MSCs in their expression of MSC markers, but lack expression of hematopoietic lineage markers and the endothelial markers CD31 and von Willebrand factor (vWF)[43,44]. Studies have also identified a periendothelial pericyte-like subpopulation of ASCs, possibly due to the inclusion of vascular elements in the SVF. These cells express CD34, as well as mesenchymal, pericytic, and smooth muscle markers, including chondroitin sulfate proteoglycan (NG2), CD140a, and CD140b[45], but are negative for CD31, CD45 and CD144. However CD34 and CD104b did not co-localize in these cells, suggesting that CD34+/CD31- cells in the adipose vasculature are not pericytes[46].

The DFAT cells initially lack expression of CD34, CD31, CD146, CD45, and pericyte markers, distinguishing them from ASCs derived from the SVF[6-9] (see below for further characterization of DFAT cells). Interestingly, lineage tracing in mice suggest that part of the stromal cells may be derived from adipocytes *in vivo*[47], suggesting that ASCs and DFAT cells in part have the same precursor cells. The DFAT cells, however, constitute a more homogeneous cell population than the ASCs, further supporting a role of the mature adipocyte fraction as a source of stem cells[48-50].

DFAT cells and iPSCs

Three major types of pluripotent stem cells have so far been identified, ESCs, iPSCs from reprogrammed adult somatic cells[51], and multilineage-differentiating stress-enduring cells, referred to as Muse cells, isolated from mesenchymal human tissues[52]. The Muse cells are considered MSCs, capable of forming cell clusters and expressing a set of genes associated with pluripotency.

All three cell types have factors that limit their use. Ethical concerns make the ESCs controversial, and heterologous transplantation of ESCs may produce immune rejection in the recipient. Transplantation of both ESCs and iPSCs run the risk of producing teratomas in the recipient because of their uncontrolled capacity of proliferation and differentiation. The paucity of Muse cells has so far been a limitation for their widespread use. Other limitations to the use of iPSCs are derived from the fact that reprogramming genes have been introduced and remain with low efficiency expression in the host cells. One of the ways to overcome this problem is to achieve efficient transgene-free reprogramming using Sendai virus[53]. Sendai virus remain in the cytoplasm and do not have the ability to integrate into the host genome. Most commonly, virus clearance is achieved by clonal propagation of primary colonies leading to isolation of sub-clones free of the viral genome. However, about 10% of the cells still have the virus after 10 passages[54]. Although human is not the natural host for Sendai virus, and the virus is non-pathogenic to humans, the potential mucosal exposure to the virus remains a concern. Therefore, identification and development of new sources of pluripotent adult stem cells remain important.

DFAT cells have been shown to express ESC markers including the POU homeodomain protein Oct4, sex determining region Y-box 2 (SOX2), myelocytomatosis oncogene (*c-Myc*), and the homeobox protein Nanog, which are key factors in maintaining pluripotency[55]. In addition, high alkaline phosphatase and telomerase activity further support similarities between DFAT cells and undifferentiated pluripotent stem cells. However, the expression of pluripotency markers decrease significantly in DFAT cells that have been cultured for longer than 2 wk. It is possible that the early expression of pluripotency markers in DFAT cells was missed in previous investigations where specific lineages were studied, causing the pluripotency in DFAT cells to be overlooked. Several investigators have also reported low levels of expression of pluripotency markers in human ASCs[56-58], and other studies have revealed similar degrees of pluripotency in DFAT cells and iPSCs[59,60].

The DFAT cells are unlike the iPSCs, in which simultaneous overexpression of the transcription factors Oct4, SOX2, c-Myc, and the Kruppel-like factor 4 leads to the generation of a pluripotent, ESC-like state in fibroblasts. After derivation from adipocytes, pluripotency emerges transiently of DFAT cells with expression of the same transcription factors as in iPSCs, as well as low levels of Nanog, stage-specific embryonic antigen (SSEA)-3, and CD105[59]. The DFAT cells are able to differentiate into cells representative of the three germ layers, with no evidence of teratoma after injection of human DFAT cells in immunodeficient mice[59]. It was recently shown that mature porcine adipocytes, in response to dedifferentiation, downregulate many genes important for lipid metabolism and upregulate genes involved in cell proliferation, cell morphology and regulation of cell differentiation[53]. By this process, the dedifferentiated adipocytes achieved the appropriate DNA methylation status, underwent gene-reprogramming, and gained stem cell properties. Thus, the available data support that dedifferentiated adipocytes have the molecular signature of a reprogrammed cell similar to pluripotent stem cells.

ADIPOCYTE AND DFAT CELL ISOLATION, AND CHARACTERIZATION

Isolation and dedifferentiation of mature adipocytes

Large lipid accumulations make the white adipocytes naturally buoyant and therefore difficult to culture. This technical difficulty has in part made their *in vitro* characteristics inaccessible for study. Additionally, they have been considered to be in the terminal stages of differentiation and lacking proliferative activity, further decreasing the interest in their *in vitro* and *in vivo* behavior on a cellular level. It is more than five decades since Rodbell[61] first succeeded in separating unilocular adipocytes from mature white fat tissue using collagenase treatment. Since then, most biochemical studies of adipocytes have made use of such dispersed cells. However, mature adipocytes do not attach to the bottom of tissue culture plates, but rather float to the surface of any given culture medium. To overcome this issue, Sugihara *et al*[9,62] proposed to use using ceiling culture as a way of culturing adipocytes. Most adipocytes lose their intracellular lipid and buoyancy with time *in vitro*. Ultimately, the cells have lost all lipids, appear fibroblastic, and proliferate to confluence. *In vivo*, tissue expanders were placed within the inguinal fat pad of rats[63]. Expanded fat pads were then autotransplanted to a distant location. Histologic analysis demonstrated that the tissue-expanded fat pads had lost over half their original volume, and the adipocytes had become elongated, fibroblast-like cells. These changes were attributed to the mechanical forces of the expander but may represent adipocyte dedifferentiation. Interestingly, after these same "atrophied" fat pads were transplanted as autografts, they regained their previous volume, suggesting adipocyte redifferentiation. This supports the concept of an adipocyte equilibrium in which dedifferentiated adipocytes may withstand ischemic insult better than differentiated adipocytes.

In the last decade, several studies have explored the plasticity of mature adipocytes and introduced to them to the stem cell field. Adipocyte dedifferentiation is readily seen *in vitro*. Matsumoto *et al*[6] showed that adipocytes containing two nuclei were occasionally detected in adipocytes before they were placed in ceiling culture, but were frequently seen after 3 d of culture. Such binuclear adipocytes were always positive for BrdU in both nuclei, suggesting that the cells had entered S-phase and the nuclei had divided. The authors also performed time-lapse fluorescence microscopy, which revealed that fibroblast-like cells were indeed generated from lipid-filled adipocytes with single nuclei through asymmetric division[6,64]. Another similar study demonstrated isolation of stem cells with characteristics of immature neural crest cells through asymmetric cell division in cultured human hair follicles *in vitro*[65]. Asymmetric cell division permits a single mother cell to generate daughter cells that are distinct in size, shape, function and fate. The generation of two progeny with different fates requires a highly regulated molecular program. In general, disruption of asymmetric cell division leads to the creation of two progeny that retain stem cell characteristics, but with reduced ability to achieve full differentiation[66-69]. As far as we have observed, the emergence of DFAT cells from mature adipocytes occurs *via* two phenomena; mature adipocytes lose their lipid content and acquire a fibroblast-like shape, and asymmetric cell division of mature adipocytes into one lipid-filled adipocyte and another small daughter cells without lipid (Figure 1). Subsequently, the cells undergo dedifferentiation without the use of inducing agents, resulting in proliferative DFAT cells.

Recent studies exploring DFAT cells describe specific purification steps to ensure, to the extent possible, the purity of the initial preparation of mature adipocytes. Indeed, the purity of the primary adipocytes is essential in the preparation of DFAT cells, as to avoid the possibility of floating adipocytes "dragging" contaminating cells with them[70]. Recently, we proposed a new method to prepare DFAT cells, using insert culture (Figure 2)[59]. In this method, DFAT cells are generated from lipid-filled mature adipocytes isolated from small pieces of subcutaneous adipose tissue or human fresh lipoaspirate, washed repeatedly with phosphate-buffered saline until the washes are clear[6,59,62]. Approximately 1 g of adipose tissue is minced and digested in 0.1% (w/v) collagenase solution (Collagenase type Ⅰ) at 37 ℃ for 1 h with gentle agitation. After filtration through nylon filters (core size 100 μm) and centrifugation at 135 g for 3 min, the floating top layer of adipocytes is collected. The adipocytes are then washed repeatedly (usually three times) in Dulbecco's Modified Eagle Medium supplemented with 20% fetal bovine serum before further use. Adipocytes intended for DFAT cell generation are floated on top of medium in culture dishes or plastic tubes to let remaining non-adipocytes detach and sink to the bottom and be discarded after centrifugation. Adipocytes from the top creamy layer (30-50 μL) are subsequently transferred to 6-well plates fitted with 70 μm-filters and incubated for 5 d in culture medium. DFAT cells derived from the adipocytes sink through the filters and attach to the bottom of the dishes. The filters with remains of the adipocytes are removed after 5 d (Figure 2). This method of preparing DFAT cells does not include attachment of the adipocytes to plastic surfaces or ceiling culture, as previously described[6-8,62,71]. In addition, this method allows the separation of the DFAT cells from the adipocytes as soon as they sink through the filter and attach to the bottom of the dish. This reduces the influence of adipocyte remnants on the surface of the medium on the characteristics of the nascent DFAT cells. We regularly collect up to 10000 DFAT cells during 5 d of collection. The inclusion of these additional steps not only enhances the purity of DFAT cells, but significantly increases the early expression of pluripotency markers



Figure 1 Dedifferentiation of adipocytes. Mature adipocytes lose their lipid content and acquire a fibroblast-like shape. Mature adipocytes also divide asymmetrically into one lipid-filled adipocyte and small daughter cells without lipid. The new lipid-free cells are referred to as DFAT cells. DFAT: Dedifferentiated fat.

previously described[59].

Characterization of DFAT cells

Most studies on the DFAT cells have concluded that they are a largely homogeneous cell population with an immunophenotype similar to those of ASCs and other MSCs[72,73]. Human ASCs are relatively heterogeneous and carry hematopoietic-associated markers such as CD11a, CD14, CD45, CD86 and HLA-DR, and low levels of the MSCs-associated markers CD13, CD29, CD34, CD44, CD63, CD73, CD90 and CD166[73,74]. On the other hand, the DFAT cells are positive for CD13, CD29, CD44, CD90, CD105, CD9, CD166 and CD54, and negative for CD14, CD31, CD34, CD45, CD66b, CD106, CD117, CD133, CD146, CD271, CD309, HLA-DR and alpha-smooth muscle cell actin[1,50,75]. Both ASCS and DFAT cells express HLA-A, -B and -C, which suggests that both cell types have allogenic transplantation potential. In addition, we detected that 7.1% of the human DFAT cells expressed SSEA-3, and that most of the human DFAT cells expressed CD105, whereas mouse DFAT cells expressed Sca-1[59]. This expression was maintained for multiple passages. However, the expression of stem cell markers in human DFAT cells varies with the donor's age, culture conditions, and the degree of differentiation.

DIFFERENTIATION POTENTIAL OF DFAT CELLS

DFAT cells have emerged as a potential cell source for regenerative medicine because of their transdifferentiation capability and similarity to ASCs and bone marrow MSCs[75-77]. Multiple studies have demonstrated differentiation of DFAT cells into multiple lineages including adipogenic, osteogenic, chondrogenic, myogenic, angiogenic and neurogenic lineages (Figure 3). To monitor the fate of DFAT cells, investigators have used DFAT cells prepared from the adipose tissue of GFP-transgenic mice for transplantation into wild type mice[64,78], or adipocyte protein 2-Cre$^{+/+}$; LacZ ROSA (R26R)+/+ double transgenic mice[79]. Human DFAT cells used for injection of immunodeficient mice were traced by anti-human mitochondria staining[59]. However, the potential need to maintain a specific cell identity once the DFAT cells have achieved a desired phenotype, or the methodology to do so, has not been assessed thus far.

Adipogenesis

Soft tissue reconstruction is an important aspect of tissue engineering, and adipose grafts are needed for minimally invasive injectable therapies in order to



Figure 2 Schematic drawing of dedifferentiated fat cell preparation using preincubation and filters. Isolated adipocytes are incubated for 24 h in culture medium, before transfer to a new dish with filter, where the adipocytes remain for five days before the filter is removed. DFAT cells are allowed to sink through the filter to the bottom of the dish. The adipocytes and filter insert are then removed, and the new DFAT cells are cultured by regular methods. ASCs: Adipose-derived stem cells; DFAT: Dedifferentiated fat.

restore soft tissue volume. The most important features of adipose tissue as a cell source might be its relative expendability and the ease with which large quantities can be obtained with minimal risk. Correctly prepared adipocytes could therefore be a useful alternative for tissue augmentation, such as breast surgery with allogeneic material or tissue flap surgery.

Previous studies have confirmed that mature adipocytes easily redifferentiate into adipocytes[6,7,11]. We demonstrated that mouse DFAT cells spontaneously underwent adipogenic differentiation without special treatment, whereas human DFAT cells required adipogenic induction[51]. Another study showed that although DFAT cells expressed lower levels of lipoprotein lipase, leptin, and glucose transporter 4 compared to mature adipocytes, they still expressed important adipogenic markers such as peroxisome proliferator-activated receptor gamma (PPARγ), C/EBPα, C/EBPβ, C/EBPδ, and sterol regulatory element-binding protein-1c[6,80]. In addition, the DFAT cells have been shown to have adipogenic capacity *in vivo*. Direct injection of DFAT cell into the subcutaneous portion over sternum of mice resulted in fat pad formation after 3 wk without the use of chemical induction[7,81]. Furthermore, it was found that that PPARγ and C/EBPα mRNA levels were higher in DFAT cells derived from intramuscular adipose tissue rather than visceral adipose tissue in pigs, suggesting a more active adipogenesis in intramuscular DFAT cells, as compared to visceral DFAT cells[82]. It implies that DFAT cells from the same donor may differ in rates of redifferentiation and expression of molecular markers depending on the depot of origin.

Osteogenesis and chondrogenesis

DFAT cells can be derived from small amounts of subcutaneous adipose tissue regardless of the age of the donors, and may be useful in cell-based therapies for a variety of diseases commonly affecting elderly subjects, including metabolic bone disorders and osteoporosis. An earlier study found that the transcription factors RUNX2 and SP7, secreted phosphoprotein 1, bone Gla protein, parathyroid hormone 1 receptor and SOX9 were expressed in DFAT cells, suggesting osteogenic and chondrogenic potentials[6]. Osteogenic differentiation was stimulated by the addition of dexamethasone, β-glycerophosphate and L-ascorbic acid-2-phosphate to the culture medium. It was also stimulated by the addition of retinoic acid, an analogue of retinol that interacts with bone morphogenetic proteins (BMPs) to limit adipogenesis and promote osteogenesis[83]. Chondrogenic induction, however, was facilitated by the addition of L-ascorbic acid-2-phosphate, proline, pyruvate, and transforming growth factor β3. Appropriate mineralization of the cells was confirmed by alkaline phosphate, Alizarin Red S and von Kossa staining, whereas chondrocyte differentiation was confirmed by Alcian Blue staining. An experiment using implantation of DFAT cells in combination with collagen-based scaffolds further showed the ability of the cells to undergo osteochondrogenesis *in vivo*[84]. Another study proposed DFAT cells as a cell source for periodontal regeneration, after the cells promoted osteogenic differentiation in co-cultures with periodontal ligament stem cells[85]. Furthermore, the ability of human DFAT cells from the buccal fat pad to undergo osteoblastic differentiation appears to be higher than that of ASCs from the same fat depot[86]. Thus, the DFAT cells may be attractive as a cell source for tissue engineering in bone disorders such as nonunion fractures and osteoporosis.

Myogenesis

Myocytes are generally divided into three categories: skeletal, cardiac and smooth muscle cells, which differ in their cellular characteristics and behaviors.



Figure 3 Schematic drawing of differentiation in dedifferentiated fat cells. The DFAT cells are able to differentiate into multiple lineages, including adipogenic, osteogenic, chondrogenic, myogenic, angiogenic and neourogenic lineages. Potential for differentiation into hepatocytes, lung cells, intestine cells and hematopoietic cells has not been reported. DFAT: Dedifferentiated fat.

Myogenesis is a multi-stage process resulting in the formation of muscular cells and tissue. It involves myoblast proliferation, secretion of fibronectin into the extracellular matrix, alignment of the myoblasts into multi-nucleated myotubes, and cell fusion[87]. The two muscle-specific transcription factors Myf5 and MyoD are known to actively regulate these processes. Treatment with 5-azacytidine (Aza-C), a demethylating agent, led to induction of MyoD and Myogenin in DFAT cells and the formation of multinucleated cells with expression of myosin heavy chain, even though Myf5 was not expressed after induction[88]. Another study found that DFAT cells underwent smooth muscle cell differentiation and contributed to the regeneration of bladder smooth muscle[78]. It also was shown that DFAT cell transplantation promoted the recovery of the sphincter muscle and improved the urethral sphincter contractility in a rat vaginal distension model[89]. Our previous study demonstrated that DFAT cells were able to differentiate into cardiomyocytes *in vitro*, and injection of DFAT cells into ischemic rat hearts induced neovascularization and supported rehabilitation of the cardiac tissue[64]. Although pluripotent stem cells have exhibited spontaneous cardiomyocyte differentiation, both *in vitro* and *in vivo*, none of the adult stem cell models studied thus far have spontaneously undergone cardiomyocyte differentiation *in vitro*, except for the DFAT cells[8,90]. Other adult stem cell models have required either co-culture with isolated cardiomyocytes or treatment with methylation inhibitors and histone deacetylase inhibitors. However, mouse DFAT cells spontaneously differentiated into functional cardiomyocytes without specific induction or genetic treatment[59]. Human DFAT cells, on the other hand, did not undergo spontaneous

cardiomyocyte differentiation, although they expressed cardiomyocyte markers after cardiogenic induction[59]. Thus, cardiomyogenic differentiation differs between mice and human DFAT cells, a difference that could be explored to uncover pathways active in spontaneous cardiomyogenesis.

Angiogenesis

Blood vessels consist of an interior lining of endothelial cells surrounded by perivascular support provided by smooth muscle cells or pericytes. Human DFAT cells without induction have been shown to express low levels of endothelial cell or progenitor markers in culture such as the vWF, CD31 or CD34[6,10,11], and to be stimulated to undergo endothelial differentiation by treatment with BMP4 and BMP9[10]. They also differentiated into endothelial cells in established *in vitro* and *in vivo* models of angiogenesis[91-93]. DFAT cells cultured in Matrigel® form tube-like structures that are stable for weeks and stain for endothelial markers, including CD31 and VE-cadherin[10]. Some researchers have proposed the tube-like structures to be a result of the perivascular nature of DFAT cells, as suggested by the expression of the pericyte-related markers CD140b and NG2[74]. Similarly, MSCs within adult mesenchymal tissues may differentiate into pericytes without induction by growth factors[94,95]. In our experiments we initially did not detect pericyte markers in DFAT cells even though they appeared later during culture. Moreover, in Matrigel®, the human DFAT cells differentiated into cells that expressed either endothelial markers or α-smooth muscle actin, which suggests that the cells undergo differentiation into multiple cell types (unpublished observations). It is possible that interactions between endothelial cells and support cells, also derived from the DFAT cells, strengthen the tube structures and promote cell maturity. Thus, the DFAT cells are able to differentiate into endothelial cells *in vitro*, and participate in neovascularization *in vivo*.

Neurogenic and other lineages

Treatments of peripheral or central nerve injuries are still suboptimal despite significant advances in neuroscience and microsurgery. The standard treatment of autologous nerve grafting is unsatisfactory because of morbidity and loss of function at the donor site. Neural progenitor cells such as ESCs and neural stem cells derived from the adult central nervous system may provide new prospects although logistical, ethical, and immunological factors are likely to limit potential applications. However, recent studies have revealed differentiation of ASCs into early neural progenitors, which has generated interest in the field of regenerative medicine. Hsueh *et al*[96] observed that, when seeded on a chitosan-coated surface, human ASCs form spheres containing up to 19.5% nestin positive cells. Ahmadi *et al*[97] further reported that, after culture in serum-free medium, 51% nestin-positive cells could be generated from human ASCs. However, Zuk *et al*[43] found that nestin was expressed in multiple cell types, including myogenic, endothelial, and hepatic cells, indicating that nestin expression alone is not suitable for the identification of neural cells, especially without functional analysis. Some studies suggest that adipose tissue stem cells are able to induce neurite outgrowth *in vitro*, as well as tissue-specific commitment to neural cell lineages and expression of the tropomyosin receptor kinase A neurotrophin receptor *in vivo*[98,99]. Most recently, a study demonstrated that ASCs differentiated into astrocytes, oligodendrocytes, and functional neurons, which were able to generate tetrodotoxin-sensitive sodium currents[100]. DFAT cells, prepared in parallel with ASCs, also had neurogenic potential and expressed neurotrophic factors such as brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. After transplantation, the DFAT cells supported functional recovery from spinal cord injury (SCI)-induced motor dysfunction in rats[101]. Furthermore, the DFAT cells promoted remyelination and inhibited glial scar formation in SCI mice, possibly through cell-autonomous as well as cell-non-autonomous effects[102]. It is possible that the neurotrophic factors secreted from the grafted DFAT cells contribute to the functional recovery. Further characterization of the capacity of DFAT cells to undergo neurogenesis, with particular focus on neurophysiologic and neurochemical signal transduction properties, is needed.

Even though hematopoietic linage differentiation has not yet been reported in DFAT cells, studies comparing porcine-derive mature adipocytes and DFAT cells suggest that such potential exists[60,103]. Upregulation of genes related to multiple lineages occurred during the dedifferentiation, including those related to hematopoietic cell differentiation.

Overall, DFAT cells appear to constitute an excellent source of cells for tissue engineering. However, the mechanisms of dedifferentiation, and whether it occurs under physiological or pathological conditions *in vivo,* need further exploration. In addition, culture conditions for the maintenance of stem cell characteristics, as well as induction of specific linages, need development. DFAT cells can also be prepared to match the individual patient, thus allowing for replacement therapies using autologous transplantation. Although no human trial has ever been reported on DFAT cells, it should not deter us from anticipating their clinical application, with focus on tissue regeneration.

CONCLUSION

Multipotent DFAT cells provide evidence of plasticity in adipocytes. The recently characterized DFAT cell model exhibit robust proliferation and multipotency potential giving them an advantage over other adult stem cell models. Compared to bone marrow derived stem cells, white adipose tissue is mostly located subcutaneously and their abundance is generally guaranteed. Further-

more, access to mature adipocytes is obtained though less invasive methods such as liposuction, which have less physical and psychological effects on the donor. Compared to ASCs, DFAT cells comprise a more homogeneous population of cells. Modified culture methods reduce the risk of contamination by cells from the stromal vascular fraction to a minimum. *In vitro* and/or *in vivo* experiments have revealed adipogenic, osteogenic, chondrogenic, myogenic, angiogenic and neourogenic differentiation potentials in DFAT cells. Moreover, the DFAT cells express ESC markers and are similar to iPS cells in certain physiological aspects. Based on the abundance, ease of preparation, homogeneity, and multi-lineage potential, the DFAT cells are uniquely suited for regenerative medicine.

REFERENCES

1 **Fonseca-Alaniz MH**, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. *J Pediatr* (Rio J) 2007; **83**: S192-S203 [PMID: 17989837 DOI: 10.2223/JPED.1709]

2 **Cao Y**. Angiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivity. *Cell Metab* 2013; **18**: 478-489 [PMID: 24035587 DOI: 10.1016/j.cmet.2013.08.008]

3 **Rosen ED**, Spiegelman BM. What we talk about when we talk about fat. *Cell* 2014; **156**: 20-44 [PMID: 24439368 DOI: 10.1016/j.cell.2013.12.012]

4 **Nadal A**, Alonso-Magdalena P, Soriano S, Ropero AB, Quesada I. The role of oestrogens in the adaptation of islets to insulin resistance. *J Physiol* 2009; **587**: 5031-5037 [PMID: 19687125 DOI: 10.1113/jphysiol.2009.177188]

5 **Al-Goblan AS**, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabetes Metab Syndr Obes* 2014; **7**: 587-591 [PMID: 25506234 DOI: 10.2147/DMSO.S67400]

6 **Matsumoto T**, Kano K, Kondo D, Fukuda N, Iribe Y, Tanaka N, Matsubara Y, Sakuma T, Satomi A, Otaki M, Ryu J, Mugishima H. Mature adipocyte-derived dedifferentiated fat cells exhibit multilineage potential. *J Cell Physiol* 2008; **215**: 210-222 [PMID: 18064604 DOI: 10.1002/jcp.21304]

7 **Nobusue H**, Endo T, Kano K. Establishment of a preadipocyte cell line derived from mature adipocytes of GFP transgenic mice and formation of adipose tissue. *Cell Tissue Res* 2008; **332**: 435-446 [PMID: 18386066 DOI: 10.1007/s00441-008-0593-9]

8 **Jumabay M**, Zhang R, Yao Y, Goldhaber JI, Boström KI. Spontaneously beating cardiomyocytes derived from white mature adipocytes. *Cardiovasc Res* 2010; **85**: 17-27 [PMID: 19643806 DOI: 10.1093/cvr/cvp267]

9 **Sugihara H**, Yonemitsu N, Miyabara S, Yun K. Primary cultures of unilocular fat cells: characteristics of growth *in vitro* and changes in differentiation properties. *Differentiation* 1986; **31**: 42-49 [PMID: 3732657 DOI: 10.1111/j.1432-0436.1986.tb00381.x]

10 **Jumabay M**, Abdmaulen R, Urs S, Heydarkhan-Hagvall S, Chazenbalk GD, Jordan MC, Roos KP, Yao Y, Boström KI. Endothelial differentiation in multipotent cells derived from mouse and human white mature adipocytes. *J Mol Cell Cardiol* 2012; **53**: 790-800 [PMID: 22999861 DOI: 10.1016/j.yjmcc.2012.09.005]

11 **Fernyhough ME**, Hausman GJ, Guan LL, Okine E, Moore SS, Dodson MV. Mature adipocytes may be a source of stem cells for tissue engineering. *Biochem Biophys Res Commun* 2008; **368**: 455-457 [PMID: 18252194 DOI: 10.1016/j.bbrc.2008.01.113]

12 **Eguizabal C**, Montserrat N, Veiga A, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation, and reprogramming: future directions in regenerative medicine. *Semin Reprod Med* 2013; **31**: 82-94 [PMID: 23329641 DOI: 10.1055/s-0032-1331802]

13 **Grafi G**, Barak S. Stress induces cell dedifferentiation in plants. *Biochim Biophys Acta* 2015; **1849**: 378-384 [PMID: 25086338 DOI: 10.1016/j.bbagrm.2014.07.015]

14 **Sandoval-Guzmán T**, Wang H, Khattak S, Schuez M, Roensch K, Nacu E, Tazaki A, Joven A, Tanaka EM, Simon A. Fundamental differences in dedifferentiation and stem cell recruitment during skeletal muscle regeneration in two salamander species. *Cell Stem Cell* 2014; **14**: 174-187 [PMID: 24268695 DOI: 10.1016/j.stem.2013.11.007]

15 **McGann CJ**, Odelberg SJ, Keating MT. Mammalian myotube dedifferentiation induced by newt regeneration extract. *Proc Natl Acad Sci USA* 2001; **98**: 13699-13704 [PMID: 11717431 DOI: 10.1073/pnas.221297398]

16 **Suzuki K**, Mitsutake N, Saenko V, Suzuki M, Matsuse M, Ohtsuru A, Kumagai A, Uga T, Yano H, Nagayama Y, Yamashita S. Dedifferentiation of human primary thyrocytes into multilineage progenitor cells without gene introduction. *PLoS One* 2011; **6**: e19354 [PMID: 21556376 DOI: 10.1371/journal.pone.0019354]

17 **Sun X**, Fu X, Han W, Zhao Y, Liu H, Sheng Z. Dedifferentiation of human terminally differentiating keratinocytes into their precursor cells induced by basic fibroblast growth factor. *Biol Pharm Bull* 2011; **34**: 1037-1045 [PMID: 21720010 DOI: 10.1248/bpb.34.1037]

18 **Hanley SC**, Assouline-Thomas B, Makhlin J, Rosenberg L. Epidermal growth factor induces adult human islet cell dedifferentiation. *J Endocrinol* 2011; **211**: 231-239 [PMID: 21933872 DOI: 10.1530/JOE-11-0213]

19 **Lee J**, Hong F, Kwon S, Kim SS, Kim DO, Kang HS, Lee SJ, Ha J, Kim SS. Activation of p38 MAPK induces cell cycle arrest *via* inhibition of Raf/ERK pathway during muscle differentiation. *Biochem Biophys Res Commun* 2002; **298**: 765-771 [PMID: 12419320 DOI: 10.1016/S0006-291X(02)02562-7]

20 **Engel FB**, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, Jiang H, Wang Y, Keating MT. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. *Genes Dev* 2005; **19**: 1175-1187 [PMID: 15870258 DOI: 10.1101/gad.1306705]

21 **Rumyantsev PP**. Interrelations of the proliferation and differentiation processes during cardiact myogenesis and regeneration. *Int Rev Cytol* 1977; **51**: 186-273 [PMID: 338537 DOI: 10.1016/S0074-7696(08)60228-4]

22 **Gassmann M**, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. *Nature* 1995; **378**: 390-394 [PMID: 7477376 DOI: 10.1038/378390a0]

23 **Lee KF**, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature* 1995; **378**: 394-398 [PMID: 7477377 DOI: 10.1038/378394a0]

24 **Yoshida A**, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. *Am J Surg Pathol* 2010; **34**: 1361-1366 [PMID: 20697254 DOI: 10.1097/PAS.0b013e3181ebcc45]

25 **Kumta SM**, Griffith JF, Chow LT, Leung PC. Primary juxtacortical chondrosarcoma dedifferentiating after 20 years. *Skeletal Radiol* 1998; **27**: 569-573 [PMID: 9840394 DOI: 10.1007/s002560050439]

26 **Kusafuka K**, Takizawa Y, Ueno T, Ishiki H, Asano R, Kamijo T, Iida Y, Ebihara M, Ota Y, Onitsuka T, Kameya T. Dedifferentiated epithelial-myoepithelial carcinoma of the parotid gland: a rare case report of immunohistochemical analysis and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; **106**: 85-91 [PMID: 18417380 DOI: 10.1016/j.tripleo.2008.01.013]

27 **Wibmer C**, Leithner A, Zielonke N, Sperl M, Windhager R. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. *Ann Oncol* 2010; **21**: 1106-1111 [PMID: 19858086 DOI: 10.1093/annonc/mdp415]

28 **Jopling C**, Sleep E, Raya M, Martí M, Raya A, Izpisúa Belmonte JC. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* 2010; **464**: 606-609

[PMID: 20336145 DOI: 10.1038/nature08899]
29 **Lafont JE**. Lack of oxygen in articular cartilage: consequences for chondrocyte biology. *Int J Exp Pathol* 2010; **91**: 99-106 [PMID: 20384821 DOI: 10.1111/j.1365-2613.2010.00707.x]
30 **Aitken KJ**, Tolg C, Panchal T, Leslie B, Yu J, Elkelini M, Sabha N, Tse DJ, Lorenzo AJ, Hassouna M, Bägli DJ. Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle. *Am J Pathol* 2010; **176**: 304-319 [PMID: 20019183 DOI: 10.2353/ajpath.2010.080834]
31 **Puri S**, Folias AE, Hebrok M. Plasticity and dedifferentiation within the pancreas: development, homeostasis, and disease. *Cell Stem Cell* 2015; **16**: 18-31 [PMID: 25465113 DOI: 10.1016/j.stem.2014.11.001]
32 **Hochedlinger K**, Jaenisch R. Nuclear reprogramming and pluripotency. *Nature* 2006; **441**: 1061-1067 [PMID: 16810240 DOI: 10.1038/nature04955]
33 **Grafi G**. Stress cycles in stem cells/iPSCs development: implications for tissue repair. *Biogerontology* 2013; **14**: 603-608 [PMID: 23852045 DOI: 10.1007/s10522-013-9445-4]
34 **Friedmann-Morvinski D**, Verma IM. Dedifferentiation and reprogramming: origins of cancer stem cells. *EMBO Rep* 2014; **15**: 244-253 [PMID: 24531722 DOI: 10.1002/embr.201338254]
35 **Hikichi T**, Matoba R, Ikeda T, Watanabe A, Yamamoto T, Yoshitake S, Tamura-Nakano M, Kimura T, Kamon M, Shimura M, Kawakami K, Okuda A, Okochi H, Inoue T, Suzuki A, Masui S. Transcription factors interfering with dedifferentiation induce cell type-specific transcriptional profiles. *Proc Natl Acad Sci USA* 2013; **110**: 6412-6417 [PMID: 23550161 DOI: 10.1073/pnas.1220200110]
36 **Talchai C**, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. *Cell* 2012; **150**: 1223-1234 [PMID: 22980982 DOI: 10.1016/j.cell.2012.07.029]
37 **Yang L**, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, Peck AB. *In vitro* trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. *Proc Natl Acad Sci USA* 2002; **99**: 8078-8083 [PMID: 12048252 DOI: 10.1073/pnas.122210699]
38 **Xie H**, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. *Cell* 2004; **117**: 663-676 [PMID: 15163413 DOI: 10.1016/S0092-8674(04)00419-2]
39 **Rodríguez-Ubreva J**, Ciudad L, Gómez-Cabrero D, Parra M, Bussmann LH, di Tullio A, Kallin EM, Tegnér J, Graf T, Ballestar E. Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes. *Nucleic Acids Res* 2012; **40**: 1954-1968 [PMID: 22086955 DOI: 10.1093/nar/gkr1015]
40 **Crisan M**, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 2008; **3**: 301-313 [PMID: 18786417 DOI: 10.1016/j.stem.2008.07.003]
41 **Ieda M**, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* 2010; **142**: 375-386 [PMID: 20691899 DOI: 10.1016/j.cell.2010.07.002]
42 **Weissman IL**, Anderson DJ, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. *Annu Rev Cell Dev Biol* 2001; **17**: 387-403 [PMID: 11687494 DOI: 10.1146/annurev.cellbio.17.1.387]
43 **Zuk PA**, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002; **13**: 4279-4295 [PMID: 12475952 DOI: 10.1091/mbc.E02-02-0105]
44 **Musina RA**, Bekchanova ES, Sukhikh GT. Comparison of mesenchymal stem cells obtained from different human tissues. *Bull Exp Biol Med* 2005; **139**: 504-509 [PMID: 16027890 DOI: 10.1007/s10517-005-0331-1]
45 **Traktuev DO**, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH, March KL. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res* 2008; **102**: 77-85 [PMID: 17967785 DOI: 10.1161/CIRCRESAHA.107.159475]
46 **Lin G**, Garcia M, Ning H, Banie L, Guo YL, Lue TF, Lin CS. Defining stem and progenitor cells within adipose tissue. *Stem Cells Dev* 2008; **17**: 1053-1063 [PMID: 18597617 DOI: 10.1089/scd.2008.0117]
47 **Gimble J**, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy* 2003; **5**: 362-369 [PMID: 14578098 DOI: 10.1080/14653240310003026]
48 **Tholpady SS**, Aojanepong C, Llull R, Jeong JH, Mason AC, Futrell JW, Ogle RC, Katz AJ. The cellular plasticity of human adipocytes. *Ann Plast Surg* 2005; **54**: 651-656 [PMID: 15900154 DOI: 10.1097/01.sap.0000158065.12174.40]
49 **Poloni A**, Maurizi G, Leoni P, Serrani F, Mancini S, Frontini A, Zingaretti MC, Siquini W, Sarzani R, Cinti S. Human dedifferentiated adipocytes show similar properties to bone marrow-derived mesenchymal stem cells. *Stem Cells* 2012; **30**: 965-974 [PMID: 22367678 DOI: 10.1002/stem.1067]
50 **Wei S**, Duarte MS, Zan L, Du M, Jiang Z, Guan L, Chen J, Hausman GJ, Dodson MV. Cellular and molecular implications of mature adipocyte dedifferentiation. *J Genomics* 2013; **1**: 5-12 [PMID: 25031650 DOI: 10.7150/jgen.3769]
51 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]
52 **Kuroda Y**, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. Unique multipotent cells in adult human mesenchymal cell populations. *Proc Natl Acad Sci USA* 2010; **107**: 8639-8643 [PMID: 20421459 DOI: 10.1073/pnas.0911647107]
53 **Fusaki N**, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* 2009; **85**: 348-362 [PMID: 19838014 DOI: 10.2183/pjab.85.348]
54 **Choi IY**, Lim H, Lee G. Efficient generation human induced pluripotent stem cells from human somatic cells with Sendai-virus. *J Vis Exp* 2014; **(86)** [PMID: 24798302 DOI: 10.3791/51406]
55 **Gao Q**, Zhao L, Song Z, Yang G. Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs. *Mol Biol Rep* 2012; **39**: 5791-5804 [PMID: 22237862 DOI: 10.1007/s11033-011-1371-4]
56 **Zuk PA**. The intracellular distribution of the ES cell totipotent markers OCT4 and Sox2 in adult stem cells differs dramatically according to commercial antibody used. *J Cell Biochem* 2009; **106**: 867-877 [PMID: 19199344 DOI: 10.1002/jcb.22054]
57 **Sun N**, Panetta NJ, Gupta DM, Wilson KD, Lee A, Jia F, Hu S, Cherry AM, Robbins RC, Longaker MT, Wu JC. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. *Proc Natl Acad Sci USA* 2009; **106**: 15720-15725 [PMID: 19805220 DOI: 10.1073/pnas.0908450106]
58 **Sachs PC**, Francis MP, Zhao M, Brumelle J, Rao RR, Elmore LW, Holt SE. Defining essential stem cell characteristics in adipose-derived stromal cells extracted from distinct anatomical sites. *Cell Tissue Res* 2012; **349**: 505-515 [PMID: 22628159 DOI: 10.1007/s00441-012-1423-7]
59 **Jumabay M**, Abdmaulen R, Ly A, Cubberly MR, Shahmirian LJ, Heydarkhan-Hagvall S, Dumesic DA, Yao Y, Boström KI. Pluripotent stem cells derived from mouse and human white mature adipocytes. *Stem Cells Transl Med* 2014; **3**: 161-171 [PMID: 24396033 DOI: 10.5966/sctm.2013-0107]
60 **Ono H**, Oki Y, Bono H, Kano K. Gene expression profiling in multipotent DFAT cells derived from mature adipocytes. *Biochem*

Biophys Res Commun 2011; **407**: 562-567 [PMID: 21419102 DOI: 10.1016/j.bbrc.2011.03.063]
61 **Rodbell M**. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. *J Biol Chem* 1964; **239**: 375-380 [PMID: 14169133]
62 **Sugihara H**, Funatsumaru S, Yonemitsu N, Miyabara S, Toda S, Hikichi Y. A simple culture method of fat cells from mature fat tissue fragments. *J Lipid Res* 1989; **30**: 1987-1995 [PMID: 2559938]
63 **von Heimburg D**, Lemperle G, Dippe B, Krüger S. Free transplantation of fat autografts expanded by tissue expanders in rats. *Br J Plast Surg* 1994; **47**: 470-476 [PMID: 7524986 DOI: 10.1016/0007-1226(94)90029-9]
64 **Jumabay M**, Matsumoto T, Yokoyama S, Kano K, Kusumi Y, Masuko T, Mitsumata M, Saito S, Hirayama A, Mugishima H, Fukuda N. Dedifferentiated fat cells convert to cardiomyocyte phenotype and repair infarcted cardiac tissue in rats. *J Mol Cell Cardiol* 2009; **47**: 565-575 [PMID: 19686758 DOI: 10.1016/j.yjmcc.2009.08.004]
65 **Yu H**, Kumar SM, Kossenkov AV, Showe L, Xu X. Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. *J Invest Dermatol* 2010; **130**: 1227-1236 [PMID: 19829300 DOI: 10.1038/jid.2009.322]
66 **Knoblich JA**. Asymmetric cell division: recent developments and their implications for tumour biology. *Nat Rev Mol Cell Biol* 2010; **11**: 849-860 [PMID: 21102610 DOI: 10.1038/nrm3010]
67 **Conklin EG**. The Mutation Theory From the Standpoint of Cytology. *Science* 1905; **21**: 525-529 [PMID: 17770960 DOI: 10.1126/science.21.536.525]
68 **Yamashita YM**, Mahowald AP, Perlin JR, Fuller MT. Asymmetric inheritance of mother versus daughter centrosome in stem cell division. *Science* 2007; **315**: 518-521 [PMID: 17255513 DOI: 10.1126/science.1134910]
69 **Bultje RS**, Castaneda-Castellanos DR, Jan LY, Jan YN, Kriegstein AR, Shi SH. Mammalian Par3 regulates progenitor cell asymmetric division *via* notch signaling in the developing neocortex. *Neuron* 2009; **63**: 189-202 [PMID: 19640478 DOI: 10.1016/j.neuron.2009.07.004]
70 **Wei S**, Bergen WG, Hausman GJ, Zan L, Dodson MV. Cell culture purity issues and DFAT cells. *Biochem Biophys Res Commun* 2013; **433**: 273-275 [PMID: 23499844 DOI: 10.1016/j.bbrc.2013.03.006]
71 **Zhang HH**, Kumar S, Barnett AH, Eggo MC. Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. *J Endocrinol* 2000; **164**: 119-128 [PMID: 10657847 DOI: 10.1677/joe.0.1640119]
72 **Kou L**, Lu XW, Wu MK, Wang H, Zhang YJ, Sato S, Shen JF. The phenotype and tissue-specific nature of multipotent cells derived from human mature adipocytes. *Biochem Biophys Res Commun* 2014; **444**: 543-548 [PMID: 24486314 DOI: 10.1016/j.bbrc.2014.01.077]
73 **Miyazaki T**, Kitagawa Y, Toriyama K, Kobori M, Torii S. Isolation of two human fibroblastic cell populations with multiple but distinct potential of mesenchymal differentiation by ceiling culture of mature fat cells from subcutaneous adipose tissue. *Differentiation* 2005; **73**: 69-78 [PMID: 15811130 DOI: 10.1111/j.1432-0436.2005.07302004.x]
74 **Shen JF**, Sugawara A, Yamashita J, Ogura H, Sato S. Dedifferentiated fat cells: an alternative source of adult multipotent cells from the adipose tissues. *Int J Oral Sci* 2011; **3**: 117-124 [PMID: 21789960 DOI: 10.4248/IJOS11044]
75 **Watson JE**, Patel NA, Carter G, Moor A, Patel R, Ghansah T, Mathur A, Murr MM, Bickford P, Gould LJ, Cooper DR. Comparison of Markers and Functional Attributes of Human Adipose-Derived Stem Cells and Dedifferentiated Adipocyte Cells from Subcutaneous Fat of an Obese Diabetic Donor. *Adv Wound Care* (New Rochelle) 2014; **3**: 219-228 [PMID: 24669358 DOI: 10.1089/wound.2013.0452]
76 **Sugawara A**, Sato S. Application of dedifferentiated fat cells for periodontal tissue regeneration. *Hum Cell* 2014; **27**: 12-21 [PMID: 24068600 DOI: 10.1007/s13577-013-0075-6]
77 **Poulos SP**, Dodson MV, Hausman GJ. Cell line models for differentiation: preadipocytes and adipocytes. *Exp Biol Med* (Maywood) 2010; **235**: 1185-1193 [PMID: 20864461 DOI: 10.1258/ebm.2010.010063]
78 **Sakuma T**, Matsumoto T, Kano K, Fukuda N, Obinata D, Yamaguchi K, Yoshida T, Takahashi S, Mugishima H. Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle-like cells and contribute to bladder tissue regeneration. *J Urol* 2009; **182**: 355-365 [PMID: 19457498 DOI: 10.1016/j.juro.2009.02.103]
79 **Urs S**, Harrington A, Liaw L, Small D. Selective expression of an aP2/Fatty Acid Binding Protein 4-Cre transgene in non-adipogenic tissues during embryonic development. *Transgenic Res* 2006; **15**: 647-653 [PMID: 16952017 DOI: 10.1007/s11248-006-9000-z]
80 **Fernyhough ME**, Hausman GJ, Dodson MV. Progeny from dedifferentiated bovine adipocytes display protracted adipogenesis. *Cells Tissues Organs* 2008; **188**: 359-372 [PMID: 18493114 DOI: 10.1159/000134007]
81 **Yagi K**, Kondo D, Okazaki Y, Kano K. A novel preadipocyte cell line established from mouse adult mature adipocytes. *Biochem Biophys Res Commun* 2004; **321**: 967-974 [PMID: 15358122 DOI: 10.1016/j.bbrc.2004.07.055]
82 **Chen J**, Dodson MV, Jiang Z. Cellular and molecular comparison of redifferentiation of intramuscular- and visceral-adipocyte derived progeny cells. *Int J Biol Sci* 2010; **6**: 80-88 [PMID: 20126314 DOI: 10.7150/ijbs.6.80]
83 **Oki Y**, Watanabe S, Endo T, Kano K. Mature adipocyte-derived dedifferentiated fat cells can trans-differentiate into osteoblasts *in vitro* and *in vivo* only by all-trans retinoic acid. *Cell Struct Funct* 2008; **33**: 211-222 [PMID: 19088398 DOI: 10.1247/csf.08038]
84 **Kikuta S**, Tanaka N, Kazama T, Kazama M, Kano K, Ryu J, Tokuhashi Y, Matsumoto T. Osteogenic effects of dedifferentiated fat cell transplantation in rabbit models of bone defect and ovariectomy-induced osteoporosis. *Tissue Eng Part A* 2013; **19**: 1792-1802 [PMID: 23566022 DOI: 10.1089/ten.TEA.2012.0380]
85 **Nakamura T**, Shinohara Y, Momozaki S, Yoshimoto T, Noguchi K. Co-stimulation with bone morphogenetic protein-9 and FK506 induces remarkable osteoblastic differentiation in rat dedifferentiated fat cells. *Biochem Biophys Res Commun* 2013; **440**: 289-294 [PMID: 24064349 DOI: 10.1016/j.bbrc.2013.09.073]
86 **Kishimoto N**, Momota Y, Hashimoto Y, Tatsumi S, Ando K, Omasa T, Kotani J. The osteoblastic differentiation ability of human dedifferentiated fat cells is higher than that of adipose stem cells from the buccal fat pad. *Clin Oral Investig* 2014; **18**: 1893-1901 [PMID: 24362590 DOI: 10.1007/s00784-013-1166-1]
87 **Vlahopoulos S**, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis VC, Schwartz RJ. Recruitment of the androgen receptor *via* serum response factor facilitates expression of a myogenic gene. *J Biol Chem* 2005; **280**: 7786-7792 [PMID: 15623502 DOI: 10.1074/jbc.M413992200]
88 **Kazama T**, Fujie M, Endo T, Kano K. Mature adipocyte-derived dedifferentiated fat cells can transdifferentiate into skeletal myocytes *in vitro*. *Biochem Biophys Res Commun* 2008; **377**: 780-785 [PMID: 18938140 DOI: 10.1016/j.bbrc.2008.10.046]
89 **Obinata D**, Matsumoto T, Ikado Y, Sakuma T, Kano K, Fukuda N, Yamaguchi K, Mugishima H, Takahashi S. Transplantation of mature adipocyte-derived dedifferentiated fat (DFAT) cells improves urethral sphincter contractility in a rat model. *Int J Urol* 2011; **18**: 827-834 [PMID: 21991997 DOI: 10.1111/j.1442-2042.2011.02865.x]
90 **Barbuti A**. The 'hearty' fat: adipocytes as a source of functional cardiomyocytes. *Cardiovasc Res* 2010; **85**: 1-2 [PMID: 19887381 DOI: 10.1093/cvr/cvp358]
91 **Soejima K**, Kashimura T, Asami T, Kazama T, Matsumoto T, Nakazawa H. Effects of mature adipocyte-derived dedifferentiated fat (DFAT) cells on generation and vascularisation of dermis-like tissue after artificial dermis grafting. *J Plast Surg Hand Surg* 2015; **49**: 25-31 [PMID: 24909822 DOI: 10.3109/2000656X.2014.920712]
92 **Poloni A**, Maurizi G, Anastasi S, Mondini E, Mattiucci D, Discepoli G, Tiberi F, Mancini S, Partelli S, Maurizi A, Cinti S,

Olivieri A, Leoni P. Plasticity of human dedifferentiated adipocytes toward endothelial cells. *Exp Hematol* 2015; **43**: 137-146 [PMID: 25448487 DOI: 10.1016/j.exphem.2014.10.003]

93 **Planat-Benard V**, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Pénicaud L, Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. *Circulation* 2004; **109**: 656-663 [PMID: 14734516 DOI: 10.1161/01.CIR.0000114522.38265.61]

94 **Natesan S**, Zhang G, Baer DG, Walters TJ, Christy RJ, Suggs LJ. A bilayer construct controls adipose-derived stem cell differentiation into endothelial cells and pericytes without growth factor stimulation. *Tissue Eng Part A* 2011; **17**: 941-953 [PMID: 21083419 DOI: 10.1089/ten.TEA.2010.0294]

95 **Bexell D**, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. *Mol Ther* 2009; **17**: 183-190 [PMID: 18985030 DOI: 10.1038/mt.2008.229]

96 **Hsueh YY**, Chiang YL, Wu CC, Lin SC. Spheroid formation and neural induction in human adipose-derived stem cells on a chitosan-coated surface. *Cells Tissues Organs* 2012; **196**: 117-128 [PMID: 22327282 DOI: 10.1159/000332045]

97 **Ahmadi N**, Razavi S, Kazemi M, Oryan S. Stability of neural differentiation in human adipose derived stem cells by two induction protocols. *Tissue Cell* 2012; **44**: 87-94 [PMID: 22178208 DOI: 10.1016/j.tice.2011.11.006]

98 **Dhar S**, Yoon ES, Kachgal S, Evans GR. Long-term maintenance of neuronally differentiated human adipose tissue-derived stem cells. *Tissue Eng* 2007; **13**: 2625-2632 [PMID: 17914923 DOI: 10.1089/ten.2007.0017]

99 **Lattanzi W**, Geloso MC, Saulnier N, Giannetti S, Puglisi MA, Corvino V, Gasbarrini A, Michetti F. Neurotrophic features of human adipose tissue-derived stromal cells: *in vitro* and *in vivo* studies. *J Biomed Biotechnol* 2011; **2011**: 468705 [PMID: 22219658 DOI: 10.1155/2011/468705]

100 **Feng N**, Han Q, Li J, Wang S, Li H, Yao X, Zhao RC. Generation of highly purified neural stem cells from human adipose-derived mesenchymal stem cells by Sox1 activation. *Stem Cells Dev* 2014; **23**: 515-529 [PMID: 24138016 DOI: 10.1089/scd.2013.0263]

101 **Ohta Y**, Takenaga M, Tokura Y, Hamaguchi A, Matsumoto T, Kano K, Mugishima H, Okano H, Igarashi R. Mature adipocyte-derived cells, dedifferentiated fat cells (DFAT), promoted functional recovery from spinal cord injury-induced motor dysfunction in rats. *Cell Transplant* 2008; **17**: 877-886 [PMID: 19069631 DOI: 10.3727/096368908786576516]

102 **Yamada H**, Ito D, Oki Y, Kitagawa M, Matsumoto T, Watari T, Kano K. Transplantation of mature adipocyte-derived dedifferentiated fat cells promotes locomotor functional recovery by remyelination and glial scar reduction after spinal cord injury in mice. *Biochem Biophys Res Commun* 2014; **454**: 341-346 [PMID: 25451251 DOI: 10.1016/j.bbrc.2014.10.082]

103 **Kono S**, Kazama T, Kano K, Harada K, Uechi M, Matsumoto T. Phenotypic and functional properties of feline dedifferentiated fat cells and adipose-derived stem cells. *Vet J* 2014; **199**: 88-96 [PMID: 24300011 DOI: 10.1016/j.tvjl.2013.10.033]

P- Reviewer: Holan V, Wakao H, Zaminy A
S- Editor: Gong XM **L- Editor**: A **E- Editor**: Jiao XK

World Journal of Stem Cells

Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4252/wjsc.v7.i10.1215

World J Stem Cells 2015 November 26; 7(10): 1215-1221
ISSN 1948-0210 (online)

ORIGINAL ARTICLE

Basic Study

Polymeric *vs* hydroxyapatite-based scaffolds on dental pulp stem cell proliferation and differentiation

Arash Khojasteh, Saeed Reza Motamedian, Maryam Rezai Rad, Mehrnoosh Hasan Shahriari, Nasser Nadjmi

Arash Khojasteh, Oral and Maxillofacial Surgery, Dental Research Center, Research Institute of Dental Sciences, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran 19839, Iran

Saeed Reza Motamedian, Maryam Rezai Rad, Mehrnoosh Hasan Shahriari, Dental Research Center , Research Institute of Dental Sciences, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran 19839, Iran

Nasser Nadjmi, the Team for Cleft and Craniofacial Anomalies, Oral and Maxillofacial Surgery, University of Antwerp, 2000 Antwerp, Belgium

Author contributions: All authors contributed to this manuscript.

Institutional review board statement: Human dental pulp stem cells were established from tooth pulp tissues of healthy volunteer donors after obtaining written consent form from patients and a protocol approved by the Dental Committee Research, School of Dentistry, Shahid Beheshti University of Medical sciences.

Institutional animal care and use committee statement: None.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: None.

Correspondence to: Nasser Nadjmi, MD, DDS, PhD, EFOMFS, Director, Professor and Coordinating Program Director, the Team for Cleft and Craniofacial Anomalies, Oral and Maxillofacial Surgery, University of Antwerp, Prinsstraat 13, 2000 Antwerp, Belgium. nasser@nadjmi.com
Telephone: +32-32-402611

Received: June 8, 2015
Peer-review started: June 10, 2015
First decision: August 4, 2015
Revised: September 30, 2015
Accepted: October 23, 2015
Article in press: October 27, 2015
Published online: November 26, 2015

Abstract

AIM: To evaluate adhesion, proliferation and differentiation of human dental pulp stem cells (hDPSCs) on four commercially available scaffold biomaterials.

METHODS: hDPSCs were isolated from human dental pulp tissues of extracted wisdom teeth and established in stem cell growth medium. hDPSCs at passage 3-5 were seeded on four commercially available scaffold biomaterials, SureOss (Allograft), Cerabone (Xenograft), PLLA (Synthetic), and OSTEON Ⅱ Collagen (Composite), for 7 and 14 d in osteogenic medium. Cell adhesion and morphology to the scaffolds were evaluated by scanning electron microscopy (SEM). Cell proliferation and differentiation into osteogenic lineage were evaluated using DNA counting and alkaline phosphatase (ALP) activity assay, respectively.

RESULTS: All scaffold biomaterials except SureOss (Allograft) supported hDPSC adhesion, proliferation and differentiation. hDPSCs seeded on PLLA (Synthetic) scaffold showed the highest cell proliferation and attachment as indicated with both SEM and DNA counting assay. Evaluating the osteogenic differentiation capability of hDPSCs on different scaffold biomaterials with ALP activity assay showed high level of ALP activity on cells cultured on PLLA (Synthetic) and OSTEON Ⅱ

Collagen (Composite) scaffolds. SEM micrographs also showed that in the presence of Cerabone (Xenograft) and OSTEON Ⅱ Collagen (Composite) scaffolds, the hDPSCs demonstrated the fibroblastic phenotype with several cytoplasmic extension, while the cells on PLLA scaffold showed the osteoblastic-like morphology, round-like shape.

CONCLUSION: PLLA scaffold supports adhesion, proliferation and osteogenic differentiation of hDPSCs. Hence, it may be useful in combination with hDPSCs for cell-based reconstructive therapy.

Key words: Human dental pulp stem cell; Stem cell; Tissue engineering; PLLA; Bone

Core tip: Recently, the plasticity of postnatal stem cells from dental origin including human dental pulp stem cells (hDPSCs) has been suggested. Their osteogenic potential makes them valuable for craniofacial bone regeneration. hDPSCs can be easily isolated from dental medical wastes, extracted teeth, and expanded *ex vivo*. Combination of numerous postnatal stem cells and three-dimensional scaffold biomaterials has been used in bone tissue engineering. Selection of an ideal scaffold biomaterial is a challenging part of reconstructive surgeries. Current study aims to evaluate behavior of hDPSCs including adhesion, proliferation, morphology and differentiation on four different scaffold biomaterials. Our finding indicates that PLLA (Synthetic) scaffold supports adhesion, proliferation and osteogenic differentiation of hDPSCs. Therefore, it can be useful for the purpose of craniofacial tissue engineering.

Khojasteh A, Motamedian SR, Rezai Rad M, Hasan Shahriari M, Nadjmi N. Polymeric *vs* hydroxyapatite-based scaffolds on dental pulp stem cell proliferation and differentiation. *World J Stem Cells* 2015; 7(10): 1215-1221 Available from: URL: http://www.wjgnet.com/1948-0210/full/v7/i10/1215.htm DOI: http://dx.doi.org/10.4252/wjsc.v7.i10.1215

INTRODUCTION

Non-healing craniofacial defects occur frequently due to various factors such as trauma, infection, tumor, and congenital deformities[1,2]. The treatment of large bone defects has been posed a challenge for reconstructive surgeons. The conventional treatment approach for treatment of craniofacial bone defects is harvesting and transplanting autogenous cancellous bone graft, particularly from ilia crest[3]. However, the surgical procedures are invasive and it usually associated with donor site morbidities and limited availability[4,5]. Another approach is utilization of allogeneic bone which is also limited by the risk of immunogenicity or disease transmission[6]. The concept of harvesting adult stem cells (ASCs) in combination with appropriate three-dimensional (3D) scaffolds have been proposed as a promising alternative approach in reconstructive surgery[7-12].

ASCs have been isolated from various tissues. In dental clinic teeth are often need to be extracted in order to avoid further complications including orthodontic treatments. Human dental pulp has been harvested from extracted teeth and shown to contain multilineage population of progenitor/stem cells, dental pulp stem cells (hDPSCs)[13,14]. The differentiation capability of hDPSCs towards the osteoblast lineage and their accessibility and ease of *ex-vivo* expansion make them suitable cell source to be considered for repair of skeletal defects[15,16].

Bone formation from hDPSCs is required a 3D structure provided by scaffolds. An ideal scaffold should provide an appropriate environment for cellular attachment, growth, and differentiation. A wide range of scaffold biomaterials have been developed for variety of applications in tissue engineering[17]. Scaffolds can be categorized as following groups: (1) Allograft; (2) Xenograft; (3) Synthetic; and (4) Composite biomaterials. In order to select a suitable scaffold for craniofacial engineering, it is necessary to evaluate the cell-scaffold interactions *in vitro*. Current study is aimed to investigate hDPSCs behavior including cell adhesion, attachment, and differentiation on four commercially available scaffolds from given groups.

MATERIALS AND METHODS

hDPSC culture

hDPSC cultures are established from dental pulp tissues isolated from extracted teeth of healthy volunteer adults (aged 18-30) as previously described[14]. Briefly, pulp tissues are gently separated from the crown and root and then digested in a solution of 0.075% collagenase type Ⅰ (Sigma-Aldrich, St. Louis, Missouri, United States) for 1 h at 37 ℃. hDPSCs are established by growing the primary cell suspension in stem cell growth medium containing DMEM-HG (Invitrogen, Grand Island, NY, United States), 10% FBS (Invitrogen, Grand Island, NY, United States) and 100 units/mL penicilliny 100 mg/mL streptomycin (Invitrogen, Grand Island, NY, United States) in T-25 flasks overnight at 37℃ and 5% CO_2, and non-adherent cells were removed by medium change. The remaining cells were cultured until they reached 80%-90% confluency. Cells were trypsinized using 0.05% Trypsin-EDTA (Invitrogen, Grand Island, NY, United States) and passaged at a ratio of 1:3 until the desired passages were reached. Passage 3-5 were used for subsequent experiments.

Scaffolds and cell seeding

Four commercially available bone-graft substitutes were studied. SureOss (HansGBR Biomaterial, Seoul, South Korea) is a freeze dried cortical bone allograft. It is a granular biomaterial with the particle size of 200-850

μm. Cerabone (Biotiss Biomaterial, Zossen, Germany) is a xenograft derived from the mineral phase of bovine bone. It is a granular biomaterial with the particle size of 0.5-1.0 mm. PLLA is a synthetic biomaterial. OSTEON Ⅱ Collagen (Dentium, Gyeonggi, South Korea) is a composite biomaterials contains HA:β-TCP = 30:70 and natural type Ⅰ collagen. It has particle size of 0.2-0.5 mm.

Approximately 100 mg of given biomaterial scaffolds were placed into 96-well plates. hDPSCs were seeded onto the scaffolds at a cell density of 10^4 cells/well in osteogenic medium (Invitrogen, Grand Island, NY, United States). The cells - scaffold constructs were maintained at 37 ℃ in a humidified 5% CO_2 atmosphere for 7 and 14 d.

Cell adhesion

hDPSCs adhesion on following scaffolds were assessed using scanning electron microscopy (SEM). Seven days after cell seeding, samples were fixed with 2.5% glutaraldehyde (MerckKGaA, Darmstadt, Germany) solution for 30 min. Specimens were then post-fixed with 1% Osmium tetroxide (Sigma-Aldrich, St. Louis, Missouri, United States). After cell fixation, the specimens were subsequently dehydrated by ascending grades of alcohol (25%, 50%, 75%, 96%, and 100% ethanol) for 15 min each step. The specimens were then allowed to dry in air. After complete drying, they were sputtered with gold and analyzed using a SEM imaging (Hitachi, Tokyo, Japan).

Cell proliferation

To determine the proliferation of hDPSCs on following scaffolds, DNA counting assay were performed using QIAamp® DNA Mini Kit, according to the manufacturer's description (Qiagen, Valencia, CA, United States). Briefly, cells at days 7 and 14 were harvested using 0.05% Trypsin-EDTA (Invitrogen, Grand Island, NY, United States). Then, cell pellets were collected by centrifugation and re-suspended in phosphate-buffed saline (PBS). DNA was collected with QIAam spin column. The amount of DNA (ng/mL) was measured using Nanodrop (Thermo Scientific, Waltham, MA, United States).

Cell differentiation

Osteogenic differentiation of hDPSCs on scaffold were evaluated at days 7 and 14 after cell seeding using alkaline phosphatase (ALP) activity assay. The cell-scaffold constructs were rinsed with PBS and homogenized in lysis buffer (pH 7.5, 10 mmol/L Tris-HCl, 1 mmol/L $MgCl_2$, and 0.05% Triton X-100). The resulting mixture was then centrifuged at 12000 rpm for 10 min at 4 ℃. The cell lysate was mixed with *p* nitrophenol phosphate substrate solution (Sigma aldrich, St. Louis, Missouri, United States) and alkaline buffer solution (Sigma aldrich, St. Louis, Missouri, United States). After incubation at 37 ℃ for 15 min, the above mixture was added to 0.5 N NaOH to stop the reaction and the absorbance at 405 nm was measured using ELIZA reader (BioTek, Winooski, VT, United States).

Statistical analysis

All quantitative data were expressed as mean ± SE. Analysis of variance and Post hoc tests was conducted for multiple comparisons. A *P* value less than 0.05 were considered to be significant.

RESULTS

Evaluation of hDPSC morphology and adhesion

The suitability of the 3D structure of scaffolds for cell seeding was assessed by observing cell morphology and adhesion using SEM imaging. SEM microphotographs after 7 d confirmed the adherence of hDPSCs in all biomaterial scaffolds (Figure 1-D) except SureOss (Allograft) (Figure 1A). Marked cell aggregation was observed on PLLA scaffold (Synthetic) (Figure 1D-F). hDPSCs were covered almost the entire PLLA scaffold surface. In contrast, fewer cells were aggregated on the surface of Cerabone (Xenograft) and OSTEON Ⅱ Collagen (Composite) scaffolds (Figure 1B and C). The adherent hDPSCs on Cerabone (Xenograft) and OSTEON Ⅱ Collagen (Composite) scaffolds demonstrated fibroblastic morphology with several cytoplasmic extension (Figure 1-F). The osteoblastic-like morphology, round-like shape, was observed on cells attached on PLLA (Synthetic) scaffold (Figure 1B, C, G and H).

Evaluation of hDPSC proliferation

The proliferation of hDPSCs on different scaffold biomaterials were monitored and quantified after 7 and 14 d culturing of the cells by means of DNA counting assay (Figure 2). DNA counting assay confirmed the SEM results. The amount of DNA was highest on PLLA group at both time points (Figure 2A and B).

Evaluation of hDPSC differentiation

The osteogenic differentiation capability of hDPSCs on different scaffold biomaterials was compared using ALP activity assay. The results are presented in Figure 3A and B. At day 14 both cells cultured on PLLA (Synthetic) and OSTEON Ⅱ Collagen (Composite) scaffolds showed high level of ALP activity compared to cells on Cerabone (Xenograft). No significant difference observed between osteogenic activity of hDPSCs on OSTEN Ⅱ Collagen and PLLA group (Figure 3B).

DISCUSSION

An ideal scaffold should interact with cells, support cell attachment and proliferation, and stimulate tissue regeneration. In current study, we investigated the hDPSC activity and growth behavior on four different 3D scaffold biomaterials. The scaffold biomaterials used



Figure 1 Scanning electron microscopy microphotographs of human dental pulp stem cells attachment and morphology on four different scaffolds. A: SureOss (Allograft); B: Cerabone (Xenograft); C: OSTEON II Collagen (Composite); D: PLLA (Synthetic); E and F: PLLA at lower magnification; G and H: Cerabone at lower magnification. Note that cells were covered almost the entire scaffold surface of PLLA (D-F). Also note that attached cells on PLLA surface showed fibroblastic morphology (D-F), whereas cells on Cerabone and OSTEON II Collagen demonstrated osteoblasic phenotype (B, C, G, H).

in this study are already commercially available for clinical applications. However, comparing their efficiency to provide structural support for hDPSCs is essential. hDPSCs has been selected for our observation, since their clinical application seems feasible. Harvesting and isolating these progenitor population are relatively easy and a sufficient number of the cells can be provided in two weeks[14,15]. In addition, since dental pulp stem



Figure 2 The quantitative analysis of human dental pulp stem cells proliferation by DNA counting assay after 7 (A) and 14 (B) d. Note that the highest amount of DNA was observed on PLLA group at both time points.



Figure 3 The assessment of osteogenic differentiation of human dental pulp stem cells by alkaline phosphatase activity assay after 7 (A) and 14 (B) d. ALP activity was highest on PLLA and OSTEON II Collagen groups at day 14. Note that no significant difference was observed between PLLA and OSTEON II Collagen. Also, note that different letters are indicated significant difference at $P \leqslant 0.05$. ALP: Alkaline phosphatase.

cells are derived from neural crest, different origin from mesoderm-derived bone marrow stem cells, they may considered better candidate for repair of damages in neural crest-derived tissues including periodontium and craniofacial defects[15,18].

We have shown that all scaffold biomaterials except SureOss (Allograft) support hDPSC adhesion, proliferation and differentiation. Among them, the highest cell proliferation was observed in the presence of PLLA, as it confirmed with both SEM and DNA counting assay. SEM showed almost all surface of PLLA scaffold was covered by adhering cells. PLLA is one of the few synthetic degradable polymers which approved by the Food and Drug Adminstration for clinical application[19] and has been used extensively in reconstructive surgery in combination with mesenchymal stem cells (MSCs)[20-22]. In our study, we have shown that MSCs derived from dental pulp tissues also are attached, proliferated, within PLLA scaffold.

In addition, SEM examination showed that cell morphology differs clearly between scaffolds. In the presence of Cerabone (Xenograft) and OSTEON Ⅱ Collagen (Composite) scaffolds, the hDPSCs demonstrated the fibroblastic phenotype, which is the typical MSC morphology[23]. However, the cells on PLLA (Synthetic) scaffold showed the round-like shape which is the typical osteoblastic phenotype[24], indicating that PLLA scaffold not only can improve cell adhesion and growth, but also upregulate the osteoblastic phenotype.

Evaluating hDPSCs adhesion, proliferation and differentiation of HA/β-TCP in composition with collagen, we have shown that despite the increase in ALP activity, the cellular attachment and proliferation was lower compared to PLLA scaffold. Phosphate Ceramics including HA and β-TCP have been described as an osteoinductive materials for many years[25-27]. Despite their similarity to mineral component of human bone, their major drawbacks including their high resorption rate and low mechanical strength[28] hampers their applications in clinics. The combination of these materials and collagen has been reported in various studies to reinforce their mechanical strength and decrease resorption rate[29-31]. Moreover, several studies have been used both collagen and HA in combination with other scaffold biomaterial in order to mimic the natural environment of the bone[32]. Akkouch *et al*[32], showed increased osteogenic capability of hDPSCs cultured on composite scaffold made of HA, collagen and poly (L-lactide-co-ε-caprolactone) (PLCL). However, there have been controversies among the literature regarding the beneficial effects of these phosphate ceramics on cellular attachment and proliferation. Study of Pereira-Junior *et al*[33], showed the slow growth of MSCs in the presence of HA granule. Similar study on MSCs seeded on β-TCP has shown the slow bone formation *in vivo*[34]. In contrast, study of Kasten *et al*[35], showed that HA ceramics supported the cellular attachment and differentiation. Ling *et al*[36], compared the attachment, proliferation and osteogenic differentiation of DPSCs on composite scaffold containing HA, collagen and poly

(L-lactide) (PLA) with β-TCP. They demonstrated that although DPSCs had more mineralization on β-TCP, cell attachment and proliferation were higher in composite scaffold of HA, collagen and PLA.

Present study was designed to evaluate these bone substitute materials in response to MSCs derived from dental pulp. However, the result of this study needs to be confirmed *in vivo,* where the interaction of cell-scaffold with host environment is an essential factor.

Our findings indicate that PLLA (Synthetic) scaffold supports adhesion, proliferation and osteogenic differentiation of hDPSCs. Therefore, it can be useful for the purpose of craniofacial tissue engineering.

COMMENTS

Background

The treatment of large non-healing craniofacial defects has been posed a challenge for reconstructive surgeries. The conventional treatment approach for treatment of craniofacial bone defects is usually associated with donor site morbidities and limited availability. The concept of harvesting adult stem cells (ASCs) in combination with appropriate three-dimensional (3D) scaffolds have been proposed as a promising alternative approach in reconstructive surgery. Human dental pulp stem cells (hDPSCs) can be easily isolated from dental medical wastes, extracted teeth, and expanded *ex vivo*. Their osteogenic capability makes them appropriate source of ASCs. Bone formation from hDPSCs is required a 3D structure provided by scaffolds which should provide an appropriate environment for cellular attachment, growth, and differentiation.

Research frontiers

A wide range of scaffold biomaterials have been developed for variety of applications in tissue engineering. Scaffolds can be categorized as following groups: (1) Allograft; (2) Xenograft; (3) Synthetic; and (4) Composite biomaterials. In order to select a suitable scaffold for craniofacial engineering, it is necessary to evaluate the cell-scaffold interactions *in vitro*. Current study is aimed to investigate hDPSCs behavior including cell adhesion, attachment, and differentiation on four commercially available scaffolds from given groups.

Innovations and breakthroughs

The authors' findings indicate that PLLA (Synthetic) scaffold supports adhesion, proliferation and osteogenic differentiation of hDPSCs.

Application

DPSCs in combination with PLLA scaffold can be useful for the purpose of craniofacial tissue engineering.

Terminology

A scaffold is an artificial designed biomaterial which mimics extra cellular matrix and it is support cellular attachment, proliferation and differentiation.

Peer-review

The study is well designed and results are clear and support the conclusions.

REFERENCES

1 **Elsalanty ME**, Genecov DG. Bone grafts in craniofacial surgery. *Craniomaxillofac Trauma Reconstr* 2009; **2**: 125-134 [PMID: 22110806 DOI: 10.1055/s-0029-1215875]

2 **Mitchel D**. An introduction to oral and maxillofacial surgery. Oxford: Oxford University Press, 2005

3 **Nkenke E**, Schultze-Mosgau S, Radespiel-Tröger M, Kloss F, Neukam FW. Morbidity of harvesting of chin grafts: a prospective study. *Clin Oral Implants Res* 2001; **12**: 495-502 [PMID: 11564110]

4 **Marx RE**, Carlson ER. Tissue banking safety: caveats and precautions for the oral and maxillofacial surgeon. *J Oral Maxillofac Surg* 1993; **51**: 1372-1379 [PMID: 8229418]

5 **Nkenke E**, Radespiel-Tröger M, Wiltfang J, Schultze-Mosgau S, Winkler G, Neukam FW. Morbidity of harvesting of retromolar bone grafts: a prospective study. *Clin Oral Implants Res* 2002; **13**: 514-521 [PMID: 12453129]

6 **Shayesteh YS**, Khojasteh A, Soleimani M, Alikhasi M, Khoshzaban A, Ahmadbeigi N. Sinus augmentation using human mesenchymal stem cells loaded into a beta-tricalcium phosphate/hydroxyapatite scaffold. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; **106**: 203-209 [PMID: 18424115 DOI: 10.1016/j.tripleo.2007]

7 **Behnia H**, Khojasteh A, Kiani MT, Khoshzaban A, Mashhadi Abbas F, Bashtar M, Dashti SG. Bone regeneration with a combination of nanocrystalline hydroxyapatite silica gel, platelet-rich growth factor, and mesenchymal stem cells: a histologic study in rabbit calvaria. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2013; **115**: e7-15 [PMID: 23312925 DOI: 10.1016/j.oooo.2011.09.034]

8 **Behnia H**, Khojasteh A, Soleimani M, Tehranchi A, Atashi A. Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: a preliminary report. *J Craniomaxillofac Surg* 2012; **40**: 2-7 [PMID: 21420310 DOI: 10.1016/j.jcms.2011.02.003]

9 **Eslaminejad MB**, Jafarian M, Khojasteh A, Abbas FM, Dehghan MM. In vivo bone formation by canine mesenchymal stem cells loaded onto HA/TCP scaffolds: qualitative and quantitative analysis. *Yakhteh* 2008; **10**: e205-e212

10 **Jafarian M**, Eslaminejad MB, Khojasteh A, Mashhadi Abbas F, Dehghan MM, Hassanizadeh R, Houshmand B. Marrow-derived mesenchymal stem cells-directed bone regeneration in the dog mandible: a comparison between biphasic calcium phosphate and natural bone mineral. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; **105**: e14-e24 [PMID: 18442730 DOI: 10.1016/j.tripleo.2008.01.010]

11 **Khojasteh A**, Behnia H, Hosseini FS, Dehghan MM, Abbasnia P, Abbas FM. The effect of PCL-TCP scaffold loaded with mesenchymal stem cells on vertical bone augmentation in dog mandible: a preliminary report. *J Biomed Mater Res B Appl Biomater* 2013; **101**: 848-854 [PMID: 23359464 DOI: 10.1002/jbm.b.32889]

12 **Rezai-Rad M**, Bova JF, Orooji M, Pepping J, Qureshi A, Del Piero F, Hayes D, Yao S. Evaluation of bone regeneration potential of dental follicle stem cells (DFSCs) for treatment of craniofacial defects. *Cytotherapy* 2015; In press [DOI: 10.1016/j.jcyt.2015.07.013]

13 **Gronthos S**, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci USA* 2000; **97**: 13625-13630 [PMID: 11087820]

14 **Morad G**, Kheiri L, Khojasteh A. Dental pulp stem cells for in vivo bone regeneration: a systematic review of literature. *Arch Oral Biol* 2013; **58**: 1818-1827 [PMID: 24095289 DOI: 10.1016/j.archoralbio]

15 **Tatullo M**, Marrelli M, Shakesheff KM, White LJ. Dental pulp stem cells: function, isolation and applications in regenerative medicine. *J Tissue Eng Regen Med* 2014 [PMID: 24850632 DOI: 10.1002/term.1899]

16 **Hilkens P**, Meschi N, Lambrechts P, Bronckaers A, Lambrichts I. Dental Stem Cells in Pulp Regeneration: Near Future or Long Road Ahead? *Stem Cells Dev* 2015; **24**: 1610-1622 [PMID: 25869156 DOI: 10.1089/scd.2014.0510]

17 **Tabatabaei FS**, Motamedian SR, Gholipour F, Khosraviani K, Khojasteh A. Craniomaxillofacial bone engineering by scaffolds loaded with stem cells: A systematic review. *J Dent Sch* 2012; **30**: e115-e131

18 **Yu J**, Wang Y, Deng Z, Tang L, Li Y, Shi J, Jin Y. Odontogenic capability: bone marrow stromal stem cells versus dental pulp stem cells. *Biol Cell* 2007; **99**: 465-474 [PMID: 17371295]

19 PLLA approval in FDA. [retrived 2015 Sept 29]. Available from: URL: http://www.fda.gov/MedicalDevices/Productsand-MedicalProcedures/CosmeticDevices/WrinkleFillers/ucm227749.htm

20 **Ardeshirylajimi A**, Mossahebi-Mohammadi M, Vakilian S, Langroudi L, Seyedjafari E, Atashi A, Soleimani M. Comparison of

osteogenic differentiation potential of human adult stem cells loaded on bioceramic-coated electrospun poly (L-lactide) nanofibres. *Cell Prolif* 2015; **48**: 47-58 [PMID: 25495212 DOI: 10.1111/cpr.12156]

21 **Richardson SM**, Curran JM, Chen R, Vaughan-Thomas A, Hunt JA, Freemont AJ, Hoyland JA. The differentiation of bone marrow mesenchymal stem cells into chondrocyte-like cells on poly-L-lactic acid (PLLA) scaffolds. *Biomaterials* 2006; **27**: 4069-4078 [PMID: 16569429]

22 **Xing SC**, Liu Y, Feng Y, Jiang C, Hu YQ, Sun W, Wang XH, Wei ZY, Qi M, Liu J, Zhai LJ, Wang ZQ. Chondrogenic differentiation of ChM-I gene transfected rat bone marrow-derived mesenchymal stem cells on 3-dimensional poly (L-lactic acid) scaffold for cartilage engineering. *Cell Biol Int* 2015; **39**: 300-309 [PMID: 25319137 DOI: 10.1002/cbin.10393]

23 **Phan SH**. Biology of fibroblasts and myofibroblasts. *Proc Am Thorac Soc* 2008; **5**: 334-337 [PMID: 18403329 DOI: 10.1513/pats.200708-146DR]

24 **Grigoriadis AE**, Heersche JN, Aubin JE. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. *J Cell Biol* 1988; **106**: 2139-2151 [PMID: 3384856]

25 **Barradas AM**, Yuan H, van Blitterswijk CA, Habibovic P. Osteoinductive biomaterials: current knowledge of properties, experimental models and biological mechanisms. *Eur Cell Mater* 2011; **21**: 407-429; discussion 429 [PMID: 21604242]

26 **Bourgeois B**, Laboux O, Obadia L, Gauthier O, Betti E, Aguado E, Daculsi G, Bouler JM. Calcium-deficient apatite: a first in vivo study concerning bone ingrowth. *J Biomed Mater Res A* 2003; **65**: 402-408 [PMID: 12746888]

27 **Yuan H**, Fernandes H, Habibovic P, de Boer J, Barradas AM, de Ruiter A, Walsh WR, van Blitterswijk CA, de Bruijn JD. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. *Proc Natl Acad Sci USA* 2010; **107**: 13614-13619 [PMID: 20643969 DOI: 10.1073/pnas.1003600107]

28 **Tjong SC**. Advances in Biomedical Sciences and Engineering. United Arab Emirates: Bentham Science Publishers, 2009

29 **Araújo MG**, Lindhe J. Ridge preservation with the use of Bio - Oss® collagen: A 6 - month study in the dog. *Clin Oral Implan Res* 2009; **20**: e433-e440 [DOI: 10.1111/j.1600-0501.2009.01705.x]

30 **Brkovic BM**, Prasad HS, Konandreas G, Milan R, Antunovic D, Sándor GK, Rohrer MD. Simple preservation of a maxillary extraction socket using beta-tricalcium phosphate with type I collagen: preliminary clinical and histomorphometric observations. *J Can Dent Assoc* 2008; **74**: 523-528 [PMID: 18644238]

31 **Fickl S**, Zuhr O, Wachtel H, Stappert CF, Stein JM, Hürzeler MB. Dimensional changes of the alveolar ridge contour after different socket preservation techniques. *J Clin Periodontol* 2008; **35**: 906-913 [PMID: 18713258 DOI: 10.1111/j.1600-051X.2008.01305.x]

32 **Akkouch A**, Zhang Z, Rouabhia M. Engineering bone tissue using human dental pulp stem cells and an osteogenic collagen-hydroxyapatite-poly (L-lactide-co-ε-caprolactone) scaffold. *J Biomater Appl* 2014; **28**: 922-936 [PMID: 23640860 DOI: 10.1177/0885328213486705]

33 **Pereira-Junior OC**, Rahal SC, Lima-Neto JF, Landim-Alvarenga Fda C, Monteiro FO. In vitro evaluation of three different biomaterials as scaffolds for canine mesenchymal stem cells. *Acta Cir Bras* 2013; **28**: 353-360 [PMID: 23702937]

34 **Lim JY**, Shaughnessy MC, Zhou Z, Noh H, Vogler EA, Donahue HJ. Surface energy effects on osteoblast spatial growth and mineralization. *Biomaterials* 2008; **29**: 1776-1784 [PMID: 18222536 DOI: 10.1016/j.biomaterials.2007.12.026]

35 **Kasten P**, Luginbühl R, van Griensven M, Barkhausen T, Krettek C, Bohner M, Bosch U. Comparison of human bone marrow stromal cells seeded on calcium-deficient hydroxyapatite, beta-tricalcium phosphate and demineralized bone matrix. *Biomaterials* 2003; **24**: 2593-2603 [PMID: 12726713]

36 **Ling LE**, Feng L, Liu HC, Wang DS, Shi ZP, Wang JC, Luo W, Lv Y. The effect of calcium phosphate composite scaffolds on the osteogenic differentiation of rabbit dental pulp stem cells. *J Biomed Mater Res A* 2015; **103**: 1732-1745 [PMID: 25131439 DOI: 10.1002/jbm.a.35303]

P- Reviewer: Bugaj AM, Duan SB
S- Editor: Ji FF **L- Editor**: A **E- Editor**: Jiao XK

Published by **Baishideng Publishing Group Inc**
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com